APPENDIX:

Plasmid DNA Maps



PLASMID NAME: rhNS-pcDNA3.1

PLASMID SIZE: 7233 bp

VECTOR DETAILS: The rhNS sequence was derived from human liver as described in Scott *et al* (1995). After the addition of *Eco*RI linkers, the rhNS transgene (bases 1 to 1806 of GenBank accession no. U30894) was cloned into the *Eco*RI site of the multiple cloning site of the pcDNA3.1 (-) vector (Invitrogen, cat. no. V95-20).





PLASMID NAME: pNS-IRES

PLASMID SIZE: 7114 bp

VECTOR DETAILS: The rhNS sequence (bases 1 to 1806 of GenBank accession no. U30894) was removed by *Eco*RI digestion from the rhNS-pcDNA3.1 vector and sub-cloned into the *Eco*RI site of the pIRES-2EGFP vector (Clontech, cat. no. 6029-1).



PLASMID NAME: pTCAV-12VK

PLASMID SIZE: 5155 bp

VECTOR DETAILS: This plasmid is derived from ptCAV-12a and has been modified by the insertion of the kanamycin/neomycin resistance gene in the *Fsp*I site of the ampicillin gene. The CAV-2 inverted terminal repeat (ITR) and the CAV-2 E2 region are homologous to the sequences in the pTG5412 plasmid. The desired transgene is subcloned into the multiple cloning site following an intervening sequence (IVS) and is driven by the CMV promoter.



PLASMID NAME: pTCAV-NS

PLASMID SIZE: 8275 bp

VECTOR DETAILS: The 5' rhNS-IRES-EGFP 3' sequence from the plasmid pNS-IRES was removed by digesting with *Not*I, blunting with Klenow fragment and then by digestion with *Nhe*I (i.e. sticky/blunt fragment). The ptCAV-12VK vector was digested with *Nhe*I and *Eco*RV (a blunt-cutter) and ligated with the rhNS-IRES-EGFP fragment to form the plasmid ptCAV-NS.



PLASMID NAME: pTG5412

PLASMID SIZE: 33375 bp

VECTOR DETAILS: This vector was constructed by TransGene SA (France) and contains the entire CAV-2 genome (Genbank accession no. J04368), including the inverted terminal repeats and E2B regions. The CAV-2 genome is cloned into a pPolyII backbone and is flanked by *Not*I linkers.

BIBLIOGRAPHY

(2005). JAX Mice Data Sheet for B6.Cg-Sgshmps3a/PstJ. [Online, accessed 9 February, 2007] http://jaxmice.jax.org/strain/003780.html

Adkins B, Du RQ (1998). Newborn mice develop balanced Th1/Th2 primary effector responses in vivo but are biased to Th2 secondary responses. *J Immunol* **160:** 4217-24.

Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. *Science* **296:** 2410-3.

Alfonso P, Pampin S, Estrada J, Rodriguez-Rey JC, Giraldo P, Sancho J, Pocovi M (2005). Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. *Blood Cells Mol Dis* **35:** 268-76.

Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, Brady RO, Barton NW, Schiffmann R (2001). The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. *J Pediatr* **138:** 539-47.

Amalfitano A, McVie-Wylie AJ, Hu H, Dawson TL, Raben N, Plotz P, Chen YT (1999). Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. *Proc Natl Acad Sci U S A* **96:** 8861-6.

Andersson U, Smith D, Jeyakumar M, Butters TD, Borja MC, Dwek RA, Platt FM (2004). Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. *Neurobiol Dis* **16:** 506-15.

Anson DS, McIntyre C, Thomas B, Koldej R, Ranieri E, Roberts A, Clements PR, Dunning K, Byers S (2007). Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. *Genet Vaccines Ther* **5:** 1.

Applegarth DA, Toone JR, Lowry RB (2000). Incidence of inborn errors of metabolism in British Columbia, 1969-1996. *Pediatrics* **105:** e10.

Arnberg N, Edlund K, Kidd AH, Wadell G (2000). Adenovirus type 37 uses sialic acid as a cellular receptor. *J Virol* **74:** 42-8.

Aronovich EL, Carmichael KP, Morizono H, Koutlas IG, Deanching M, Hoganson G, Fischer A, Whitley CB (2000). Canine heparan sulfate sulfamidase and the molecular pathology underlying Sanfilippo syndrome type A in Dachshunds. *Genomics* **68:** 80-84.

Aronovich EL, Johnston JM, Wang P, Giger U, Whitley CB (2001). Molecular basis of mucopolysaccharidosis type IIIB in emu (Dromaius novaehollandiae): An avian model of Sanfilippo syndrome type B. *Genomics* **74:** 299-305.

Astur RS, Taylor LB, Mamelak AN, Philpott L, Sutherland RJ (2002). Humans with hippocampus damage display severe spatial memory impairments in a virtual Morris water task. *Behav Brain Res* **132:** 77-84.

Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, Kohlschutter A, Kampmann C, Beck M (2005). Cumulative incidence rates of the mucopolysaccharidoses in Germany. *J Inherit Metab Dis* **28:** 1011-7.

Barsoum SC, Milgram W, Mackay W, Coblentz C, Delaney KH, Kwiecien JM, Kruth SA, Chang PL (2003). Delivery of recombinant gene product to canine brain with the use of microencapsulation. *J Lab Clin Med* **142:** 399-413.

Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, al. e (1991). Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. *N Engl J Med* **342:** 1464-1470.

Bastedo L, Sands MS, Lambert DT, Pisa MA, Birkenmeier E, Chang PL (1994). Behavioral consequences of bone marrow transplantation in the treatment of murine mucopolysaccharidosis type VII. *J Clin Invest* **94:** 1180-6.

Baum C, Kustikova O, Modlich U, Li Z, Fehse B (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. *Hum Gene Ther* **17:** 253-63.

Bax MC, Colville GA (1995). Behaviour in mucopolysaccharide disorders. *Arch Dis Child* **73:** 77-81.

Beesley CE, Young EP, Vellodi A, Winchester BG (2000). Mutational analysis of Sanfilippo syndrome type A (MPS IIIA): identification of 13 novel mutations. *J Med Genet* **37:** 704-7.

Berenjian S, Akusjarvi G (2006). Binary AdEasy vector systems designed for Tet-ON or Tet-OFF regulated control of transgene expression. *Virus Res* **115:** 16-23.

Berg T, Hopwood JJ (2002). Alpha-mannosidosis in the guinea pig: cloning of the lysosomal alpha-mannosidase cDNA and identification of a missense mutation causing alpha-mannosidosis. *Biochim Biophys Acta* **1586:** 169-176.

Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. *Science* **275:** 1320-3.

Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, Wickham T, Crowell RL, Finberg RW (1998). The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. *J Virol* **72:** 415-9.

Berget SM, Moore C, Sharp PA (1977). Spliced segments at the 5' terminus of adenovirus 2 late mRNA. *Proc Natl Acad Sci U S A* **74:** 3171-5.

Berry HK (1987). Screening for mucopolysaccharide disorders with the Berry spot test. *Clin Biochem* **20:** 365-71.

Bertoglio LJ, Carobrez AP (2000). Previous maze experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety. *Behav Brain Res* **108:** 197-203.

Bester AC, Schwartz M, Schmidt M, Garrigue A, Hacein-Bey-Abina S, Cavazzana-Calvo M, Ben-Porat N, Von Kalle C, Fischer A, Kerem B (2006). Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. *Gene Ther* **13:** 1057-9.

Bhat NR, Fan F (2002). Adenovirus infection induces microglial activation: involvement of mitogen-activated protein kinase pathways. *Brain Res* **948:** 93-101.

Bhattacharyya R, Gliddon B, Beccari T, Hopwood JJ, Stanley P (2001). A novel missense mutation in the lysosomal sulfamidase is the basis of MPS III A in a spontaneous mouse mutant. *Glycobiology* **11:** 99-103.

Bhaumik M, Muller VJ, Rozaklis T, Johnson L, Dobrenis K, Bhattacharyya R, Wurzelmann S, Finamore P, Hopwood JJ, Walkley SU, Stanley P (1999). A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). *Glycobiology* **9:** 1389-1396.

Bielicki J, Hopwood JJ, Melville EL, Anson DS (1998). Recombinant Human Sulphamidase - Expression, Amplification, Purification and Characterization. *Biochem J* **329:** 145-150.

Biffi A, Naldini L (2005). Gene therapy of storage disorders by retroviral and lentiviral vectors. *Hum Gene Ther* **16:** 1133-42.

Bilbao R, Reay DP, Wu E, Zheng H, Biermann V, Kochanek S, Clemens PR (2005). Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero. *Gene Ther* **12:** 39-47.

Birkenmeier EH, Barker JE, Vogler CA, Kyle JW, Sly WS, Gwynn B, Levy B, Pegors C (1991). Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. *Blood* **78:** 3081-92.

Bitter T, Muir HM (1962). A modified uronic acid carbazole reaction. *Anal Biochem* **4:** 330-4.

Blanch L, Weber B, Guo X-H, Scott HS, Hopwood JJ (1997). Molecular defects in Sanfilippo syndrome type A. *Hum Mol Genet* **6:** 787-791.

Boguszewski P, Zagrodzka J (2002). Emotional changes related to age in rats--a behavioral analysis. *Behav Brain Res* **133:** 323-32.

Bond CS, Clements PR, Ashby SJ, Collyer CA, Harrop SJ, Hopwood JJ, Guss JM (1997). Structure of a Human Lysosomal Sulfatase. *Structure* **5:** 277-289.

Bosch A, Perret E, Desmaris N, Heard JM (2000a). Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. *Mol Ther* **1:** 63-70.

Bosch A, Perret E, Desmaris N, Trono D, Heard J (2000b). Reversal of Pathology in the Entire Brain of Mucopolysaccharidosis Type VII Mice after Lentivirus-Mediated Gene Transfer. *Hum Gene Ther* **11:** 1139-1150.

Bouchard S, MacKenzie TC, Radu AP, Hayashi S, Peranteau WH, Chirmule N, Flake AW (2003). Long-term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno-associated viral vectors in mice. *J Gene Med* **5:** 941-50.

Bourgoin C, Emiliani C, Kremer EJ, Gelot A, Tancini B, Gravel RA, Drugan C, Orlacchio A, Poenaru L, Caillaud C (2003). Widespread distribution of beta-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol. *Gene Ther* **10:** 1841-9.

Breslau N, Schultz L, Peterson E (1995). Sex differences in depression: a role for preexisting anxiety. *Psychiatry Res* **58:** 1-12.

Brooks AI, Stein CS, Hughes SM, Heth J, McCray PM, Sauter SL, Johnston JC, Cory-Slechta DA, Federoff HJ, Davidson BL (2002). Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. *Proc Natl Acad Sci U S A* **99:** 6216-6221.

Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, Rubanyi GM (2004). Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. *J Gene Med* **6:** 395-404.

Brown PD, Davies SL, Speake T, Millar ID (2004). Molecular mechanisms of cerebrospinal fluid production. *Neuroscience* **129:** 957-70.

Brown WJ, Goodhouse J, Farquhar MG (1986). Mannose-6-phosphate receptors for lysosomal enzymes cycle between the Golgi complex and endosomes. *J Cell Biol* **103:** 1235-47.

Buchet D, Serguera C, Zennou W, Charneau P, Mallet J (2002). Long-term expression of beta-glucuronidase by genetically modified human neural progenitor cells grafted into the mouse central nervous system. *Mol Cell Neurosci* **19:** 389-401.

Bulow HE, Hobert O (2006). The molecular diversity of glycosaminoglycans shapes animal development. *Annu Rev Cell Dev Biol* **22:** 375-407.

Bunge S, Ince H, Steglich C, Kleijer WJ, Beck M, Zaremba J, Vandiggelen OP, Weber B, Hopwood JJ, Gal A (1997). Identification of 16 Sulfamidase Gene Mutations Including the Common R74C in Patients with Mucopolysaccharidosis Type IIIA (Sanfilippo A). *Hum Mutat* **10:** 479-485.

Buonavoglia C, Martella V (2007). Canine respiratory viruses. *Vet Res* **38:** 355-73.

Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. *Mol Ther* **10:** 302-17.

Byrnes AP, MacLaren RE, Charlton HM (1996). Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. *J Neurosci* **16:** 3045-55.

Byrnes AP, Rusby JE, Wood MJ, Charlton HM (1995). Adenovirus gene transfer causes inflammation in the brain. *Neuroscience* **66:** 1015-24.

Camassola M, Braga LM, Delgado-Canedo A, Dalberto TP, Matte U, Burin M, Giugliani R, Nardi NB (2005). Nonviral in vivo gene transfer in the mucopolysaccharidosis I murine model. *J Inherit Metab Dis* **28:** 1035-43.

Cardone M, Polito VA, Pepe S, Mann L, D'Azzo A, Auricchio A, Ballabio A, Cosma MP (2006). Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. *Hum Mol Genet*.

Carobrez AP, Bertoglio LJ (2005). Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. *Neurosci Biobehav Rev* **29:** 1193-205.

Carson SD, Chapman NN, Tracy SM (1997). Purification of the putative coxsackievirus B receptor from HeLa cells. *Biochem Biophys Res Commun* **233:** 325-8.

Cartmell T, Southgate T, Rees GS, Castro MG, Lowenstein PR, Luheshi GN (1999). Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain. *J Neurosci* **19:** 1517-23.

Cavalcante LA, Garcia-Abreu J, Mendes FA, Moura Neto V, Silva LC, Onofre G, Weissmuller G, Carvalho SL (2003). Sulfated proteoglycans as modulators of neuronal migration and axonal decussation in the developing midbrain. *Braz J Med Biol Res* **36:** 993-1002.

Cavanagh KT, Leipprandt JR, Jones MZ, Friderici K (1995). Molecular defect of caprine N-acetylglucosamine-6-sulphatase deficiency. A single base substitution creates a stop codon in the 5'-region of the coding sequence. *J Inherit Metab Dis* **18:** 96.

Chang PL, Lambert DT, Pisa MA (1993). Behavioural abnormalities in a murine model of a human lysosomal storage disease. *Neuroreport* **4:** 507-10.

Charles PC, Chen X, Horwitz MS, Brosnan CF (1999a). Differential chemokine induction by the mouse adenovirus type-1 in the central nervous system of susceptible and resistant strains of mice. *J Neurovirol* **5:** 55-64.

Charles PC, Weber KS, Cipriani B, Brosnan CF (1999b). Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias. *J Neuroimmunol* **100:** 64-73.

Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M (1996). Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. *J Virol* **70:** 4805-10.

Chen F, Vitry S, Hocquemiller M, Desmaris N, Ausseil J, Heard JM (2006). Alpha-l-Iduronidase transport in neurites. *Mol Genet Metab* **87:** 349-58.

Chen J, Zajac AJ, McPherson SA, Hsu HC, Yang P, Wu Q, Xu X, Wang X, Fujihashi K, Curiel DT, Mountz JD (2005). Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevation. *Gene Ther* **12:** 1079-88.

Chih-Kuang C, Shuan-Pei L, Shyue-Jye L, Tuen-Jen W (2002). MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in sanfilippo and morquio syndromes. *J Clin Lab Anal* **16:** 253-8.

Chillon M, Kremer EJ (2001). Trafficking and propagation of canine adenovirus vectors lacking a known integrin-interacting motif. *Hum Gene Ther* **12:** 1815-23.

Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999). Immune responses to adenovirus and adeno-associated virus in humans. *Gene Ther* **6:** 1574-83.

Christ M, Lusky M, Stoeckel F, Dreyer D, Dieterle A, Michou AI, Pavirani A, Mehtali M (1997). Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. *Immunol Lett* **57:** 19-25.

Christenson SD, Lake KD, Ooboshi H, Faraci FM, Davidson BL, Heistad DD (1998). Adenovirus-mediated gene transfer in vivo to cerebral blood vessels and perivascular tissue in mice. *Stroke* **29:** 1411-5.

Chung S, Ma X, Liu Y, Lee D, Tittiger M, Ponder KP (2007). Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. *Mol Genet Metab* **90:** 181-92.

Ciron C, Desmaris N, Colle MA, Raoul S, Joussemet B, Verot L, Ausseil J, Froissart R, Roux F, Cherel Y, Ferry N, Lajat Y, Schwartz B, Vanier MT, Maire I, Tardieu M, Moullier P, Heard JM (2006). Gene therapy of the brain in the dog model of Hurler's syndrome. *Ann Neurol* **60:** 204-13.

Cleary MA, Wraith JE (1993). Management of mucopolysaccharidosis type III. *Arch Dis Child* **69:** 403-6.

Coelho JC, Wajner M, Burin MG, Vargas CR, Giugliani R (1997). Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism. *Eur J Pediatr* **156:** 650-4.

Colville GA, Watters JP, Yule W, Bax M (1996). Sleep problems in children with Sanfilippo syndrome. *Dev Med Child Neurol* **38:** 538-44.

Constantopoulos G, Iqbal K, Dekaban AS (1980). Mucopolysaccharidosis types IH, IS, II, and IIIA: glycosaminoglycans and lipids of isolated brain cells and other fractions from autopsied tissues. *J Neurochem* **34:** 1399-411.

Cosma MP, Pepe S, Annunziata I, Newbold RF, Grompe M, Parenti G, Ballabio A (2003). The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. *Cell* **113:** 445-56.

Costanzi E, Beccari T, Aisa MC, Tiribuzi R, Hopwood JJ, Orlacchio A (2003). Mouse sulphamidase gene: characterization of the promoter region of the gene and expression in mouse tissues. *Gene* **310:** 143-9.

Costanzi E, Beccari T, Stinchi S, Bibi L, Hopwood JJ, Orlacchio A (2000). Gene encoding the mouse sulphamidase: cDNA cloning, structure, and chromosomal mapping. *Mamm Genome* **11:** 436-439.

Couzin J, Kaiser J (2005). Gene therapy. As Gelsinger case ends, gene therapy suffers another blow. *Science* **307:** 1028.

Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A (2000). Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. *Lancet* **355:** 1481-5.

Cox-Brinkman J, Boelens JJ, Wraith JE, O'Meara A, Veys P, Wijburg FA, Wulffraat N, Wynn RF (2006). Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. *Bone Marrow Transplant* **38:** 17-21.

Crawley AC, Gliddon BL, Auclair D, Brodie SL, Hirte C, King BM, Fuller M, Hemsley KM, Hopwood JJ (2006a). Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. *Brain Res* **1104:** 1-17.

Crawley AC, Jones MZ, Bonning LE, Finnie JW, Hopwood JJ (1999). alpha-Mannosidosis in the Guinea Pig: A New Animal Model for Lysosomal Storage Diseases. *Pediatr Res* **46:** 501-509.

Crawley AC, King B, Berg T, Meikle PJ, Hopwood JJ (2006b). Enzyme replacement therapy in alpha-mannosidosis guinea-pigs. *Mol Genet Metab* **89:** 48-57.

Crawley AC, Walkley SU (in press). Developmental Analysis of CNS Pathology in the Lysosomal Storage Disease a-Mannosidosis. *J Neuropathol Exp Neurol*.

Crawley JN (1999). Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. *Brain Res* **835:** 18-26.

Crawley JN (2000). *What's wrong with my mouse? Behavioural Phenotyping of Transgenic and Knockout Mice*. Wiley-Liss: New York.

Cregan SP, MacLaurin J, Gendron TF, Callaghan SM, Park DS, Parks RJ, Graham FL, Morley P, Slack RS (2000). Helper-dependent adenovirus vectors: their use as a gene delivery system to neurons. *Gene Ther* **7:** 1200-9.

Cressant A, Desmaris N, Verot L, Brejot T, Froissart R, Vanier MT, Maire I, Heard JM (2004). Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. *J Neurosci* **24:** 10229-39.

Croyle MA, Chirmule N, Zhang Y, Wilson JM (2001). "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. *J Virol* **75:** 4792-801.

Croyle MA, Chirmule N, Zhang Y, Wilson JM (2002). PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. *Hum Gene Ther* **13:** 1887-900.

Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P, Souweidane M, Hosain S, Heier L, Ballon D, Dinner M, Wisniewski K, Kaplitt M, Greenwald BM, Howell JD, Strybing K, Dyke J, Voss H (2004). Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. *Hum Gene Ther* **15:** 1131-54.

Cusack S (2005). Adenovirus complex structures. *Curr Opin Struct Biol* **15:** 237-43.

Dahms NM, Lobel P, Kornfeld S (1989). Mannose 6-phosphate receptors and lysosomal enzyme targeting. *J Biol Chem* **264:** 12115-8.

Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. *Proc Natl Acad Sci U S A* **92:** 1401-5.

Daly TM, Ohlemiller KK, Roberts MS, Vogler CA, Sands MS (2001). Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. *Gene Ther* **8:** 1291-1298.

Davidson EA, Meyer K (1954). Chondroitin, a new mucopolysaccharide. *J Biol Chem* **211:** 605-11.

Davis M (1992). The role of the amygdala in fear and anxiety. *Annu Rev Neurosci* **15:** 353-75.

Davison AJ, Benko M, Harrach B (2003). Genetic content and evolution of adenoviruses. *J Gen Virol* **84:** 2895-908.

De Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmans F (1955). Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. *Biochem J* **60:** 604-17.

de Jong JG, Hasselman JJ, van Landeghem AA, Vader HL, Wevers RA (1991). The spot test is not a reliable screening procedure for mucopolysaccharidoses. *Clin Chem* **37:** 572-5.

de Jong JG, Wevers RA, Laarakkers C, Poorthuis BJ (1989). Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. *Clin Chem* **35:** 1472-7.

de Pablo R, Chabas A, Coll MJ, Vilageliu L, Grinberg D (2006). Inhibition of the EXT1 gene expressions by RNA interference as a therapeutic approach for Sanfilippo A syndrome. In: *9th International Symposium on Mucopolysaccharide and Related Diseases*: Venice, Italy, pp 65.

Dean MF, Muir H, Benson PF, Button LR, Batchelor JR, Bewick M (1975). Increased breakdown of glycosaminoglycans and appearance of corrective enzyme after skin transplants in Hunter syndrome. *Nature* **257:** 609-12.

Dean MF, Muir H, Benson PF, Button LR, Boylston A, Mowbray J (1976). Enzyme replacement therapy by fibroblast transplantation in a case of Hunter syndrome. *Nature* **261:** 323-5.

Dean MF, Stevens RL, Muir H, Benson PF, Button LR, Anderson RL, Boylston A, Mowbray J (1979). Enzyme replacement therapy by fibroblast transplantation: long-term biochemical study in three cases of Hunter's syndrome. *J Clin Invest* **63:** 138-46.

Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G (2000). Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. *Virology* **268:** 382-90.

DeMatteo RP, Chu G, Ahn M, Chang E, Barker CF, Markmann JF (1997). Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression. *J Virol* **71:** 5330-5.

Desmaris N, Verot L, Puech JP, Caillaud C, Vanier MT, Heard JM (2004). Prevention of neuropathology in the mouse model of Hurler syndrome. *Ann Neurol* **56:** 68-76.

Detrait ER, Bowers WJ, Halterman MW, Giuliano RE, Bennice L, Federoff HJ, Richfield EK (2002). Reporter gene transfer induces apoptosis in primary cortical neurons. *Mol Ther* **5:** 723-30.

D'Hooge R, De Deyn PP (2001). Applications of the Morris water maze in the study of learning and memory. *Brain Res Brain Res Rev* **36:** 60-90.

Di Domenico C, Villani GR, Di Napoli D, Reyero EG, Lombardo A, Naldini L, Di Natale P (2005). Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. *Hum Gene Ther* **16:** 81-90.

Di Ferrante N, Nichols BL, Donnelly PV, Neri G, Hrgovcic R, Berglund RK (1971). Induced degradation of glycosaminoglycans in Hurler's and Hunter's syndromes by plasma infusion. *Proc Natl Acad Sci U S A* **68:** 303-7.

Di Natale P, Balzano, N., Esposito, S. & Villani, G.R.D. (1998). Identification of Molecular Defects in Italian Sanfilippo A Patients Including 13 Novel Mutations. *Hum Mutat* **11:** 313-320.

Di Natale P, Di Domenico C, Gargiulo N, Castaldo S, Gonzalez YRE, Mithbaokar P, De Felice M, Follenzi A, Naldini L, Villani GR (2005). Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector. *Biochem J* **388:** 639-46.

Di Natale P, Villani GR, Di Domenico C, Daniele A, Dionisi Vici C, Bartuli A (2003). Analysis of Sanfilippo A gene mutations in a large pedigree. *Clin Genet* **63:** 314-8.

DiCioccio RA, Miller AL (1991). Biosynthesis, processing, and secretion of alpha-L-fucosidase in lymphoid cells from patients with I-cell disease and pseudo-Hurler polydystrophy. *Glycobiology* **1:** 595-604.

Dickson P, McEntee M, Vogler C, Le S, Levy B, Peinovich M, Hanson S, Passage M, Kakkis E (2007). Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid. *Mol Genet Metab* **91:** 61-8.

Dickson P, Vogler C, Levy B, McEntee M, Passage M, Le S, Snider S, Manuel H, Kakkis E (2006). High-dose intravenous enzyme replacement therapy treats brain storage in tolerant MPS I dogs. In: *9th International Symposium on Mucopolysaccharide and Related Diseases*: Venice, Italy, pp supplementary page.

Dierks T, Schmidt B, Borissenko LV, Peng J, Preusser A, Mariappan M, von Figura K (2003). Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. *Cell* **113:** 435-44.

Diez-Roux G, Ballabio A (2005). Sulfatases and human disease. *Annu Rev Genomics Hum Genet* **6:** 355-79.

Ding E, Hu H, Hodges B, Migone F, Serra D, Xu F, Chen Y-T, Amalfitano A (2002). Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. *Mol Ther* **5:** 436-445.

Dittmer F, Ulbrich EJ, Hafner A, Schmahl W, Meister T, Pohlmann R, von Figura K (1999). Alternative mechanisms for trafficking of lysosomal enzymes in mannose 6-phosphate receptor-deficient mice are cell type-specific. *J Cell Sci* **112 (Pt 10):** 1591-7.

Donsante A, Levy B, Vogler C, Sands MS (2007). Clinical response to persistent, low-level beta-glucuronidase expression in the murine model of mucopolysaccharidosis type VII. *J Inherit Metab Dis* **30:** 227-38.

Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, Flotte T, Campbell-Thompson M, Daly T, Sands MS (2001). Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. *Gene Ther* **8:** 1343-1346.

Dorfman A, Lorincz AE (1957). Occurrence of Urinary Acid Mucopolysaccharides in the Hurler Syndrome. *Proc Natl Acad Sci U S A* **43:** 443-6.

Driesse MJ, Esandi MC, Kros JM, Avezaat CJ, Vecht C, Zurcher C, van der Velde I, Valerio D, Bout A, Sillevis Smitt PA (2000). Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. *Gene Ther* **7:** 1401-9.

Du H, Heur M, Witte DP, Ameis D, Grabowski GA (2002a). Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice. *Hum Gene Ther* **13:** 1361-72.

Du M, Jones JR, Lanier J, Keeling KM, Lindsey JR, Tousson A, Bebok Z, Whitsett JA, Dey CR, Colledge WH, Evans MJ, Sorscher EJ, Bedwell DM (2002b). Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. *J Mol Med* **80:** 595-604.

Dunder U, Kaartinen V, Valtonen P, Vaananen E, Kosma VM, Heisterkamp N, Groffen J, Mononen I (2000). Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. *FASEB J* **14:** 361-367.

Durham HD, Alonso-Vanegas MA, Sadikot AF, Zhu L, Lochmuller H, Massie B, Nalbantoglu J, Karpati G (1997). The immunosuppressant FK506 prolongs transgene expression in brain following adenovirus-mediated gene transfer. *Neuroreport* **8:** 2111-5.

Easton RM, Johnson EM, Creedon DJ (1998). Analysis of events leading to neuronal death after infection with E1-deficient adenoviral vectors. *Mol Cell Neurosci* **11:** 334-47.

Edelstein ML (2007). Gene Therapy Clinical Trials Worldwide. [Online, accessed 6 February, 2007] http://www.wiley.co.uk/genmed/clinical/

Ehrhardt A, Xu H, Huang Z, Engler JA, Kay MA (2005). A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. *Mol Ther* **11:** 695-706.

Elliger SS, Elliger CA, Aguilar CP, Raju NR, Watson GL (1999). Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. *Gene Ther* **6:** 1175-1178.

Elliger SS, Elliger CA, Lang C, Watson GL (2002). Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. *Mol Ther* **5:** 617-626.

Ellinwood NM, Henthorn PS, Giger U, Haskins ME (2003a). Mucopolysaccharidosis type IIIB: Identification of the causative mutation in the canine model [abstract]. *Am J Hum Genet* **73:** 449.

Ellinwood NM, Vite CH, Haskins ME (2004). Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. *J Gene Med* **6:** 481-506.

Ellinwood NM, Wang P, Skeen T, Sharp NJ, Cesta M, Decker S, Edwards NJ, Bublot I, Thompson JN, Bush W, Hardam E, Haskins ME, Giger U (2003b). A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs. *J Inherit Metab Dis* **26:** 489-504.

Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A (2004). Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. *J Inherit Metab Dis* **27:** 757-66.

Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001). International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. *N Engl J Med* **345:** 9-16.

Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, Wenger DA, Pietryga D, Wall D, Champagne M, Morse R, Krivit W, Kurtzberg J (2005). Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. *N Engl J Med* **352:** 2069-81.

Eskelinen EL, Tanaka Y, Saftig P (2003). At the acidic edge: emerging functions for lysosomal membrane proteins. *Trends Cell Biol* **13:** 137-45.

Espejo EF (1997). Effects of weekly or daily exposure to the elevated plus-maze in male mice. *Behav Brain Res* **87:** 233-8.

Esposito S, Balzano N, Daniele A, Villani GRD, Perkins K, Weber B, Hopwood JJ, Di Natale P (2000). Heparan N-sulfatase gene: two novel mutations and transient expression of 15 defects. *Biochim Biophys Acta* **1501:** 1-11.

Eto Y, Gao JQ, Sekiguchi F, Kurachi S, Katayama K, Maeda M, Kawasaki K, Mizuguchi H, Hayakawa T, Tsutsumi Y, Mayumi T, Nakagawa S (2005). PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. *J Gene Med* **7:** 604-12.

Eto Y, Shen JS, Meng XL, Ohashi T (2004). Treatment of lysosomal storage disorders: cell therapy and gene therapy. *J Inherit Metab Dis* **27:** 411-5.

Fan X, Zhang H, Zhang S, Bagshaw RD, Tropak MB, Callahan JW, Mahuran DJ (2006). Identification of the gene encoding the enzyme deficient in mucopolysaccharidosis IIIC (Sanfilippo disease type C). *Am J Hum Genet* **79:** 738-44.

Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, et al. (1995). Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. *Hum Gene Ther* **6:** 1039-44.

Fathallah-Shaykh HM, Kafrouni AI, Zhao LJ, Diaz-Arrastia R, Garcia JA, Frawley WH, Forman J (2000). Demyelination but no cognitive, motor or behavioral deficits after adenovirus-mediated gene transfer into the brain. *Gene Ther* **7:** 2094-8.

Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, Schoemaker R, Veghel R, Houtsmuller A, Schultheiss HP, Lamers J, Poller W (1999). Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. *Gene Ther* **6:** 1520-35.

Fernandes C, File SE (1996). The influence of open arm ledges and maze experience in the elevated plus-maze. *Pharmacol Biochem Behav* **54:** 31-40.

Fessler SP, Delgado-Lopez F, Horwitz MS (2004). Mechanisms of E3 modulation of immune and inflammatory responses. *Curr Top Microbiol Immunol* **273:** 113-35.

Fischer A, Carmichael KP, Munnell JF, Jhabvala P, Thompson JN, Matalon R, Jezyk PF, Wang P, Giger U (1998). Sulfamidase deficiency in a family of Dachshunds: a canine model of mucopolysaccharidosis IIIA (Sanfilippo A). *Pediatr Res* **44:** 74-82.

Fischer A, Hacein-Bey-Abina S, Lagresle C, Garrigue A, Cavazana-Calvo M (2005). Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome [abstract]. *Bull Acad Natl Med* **189:** 779-85; discussion 786-8.

Fleury S, Driscoll R, Simeoni E, Dudler J, von Segesser LK, Kappenberger L, Vassalli G (2004). Helper-dependent adenovirus vectors devoid of all viral genes cause less myocardial inflammation compared with first-generation adenovirus vectors. *Basic Res Cardiol* **99:** 247-56.

Flomenberg P, Piaskowski V, Truitt RL, Casper JT (1995). Characterization of human proliferative T cell responses to adenovirus. *J Infect Dis* **171:** 1090-6.

Fraldi A, Biffi A, Lombardi A, Visigalli I, Pepe S, Settembre C, Nusco E, Auricchio A, Naldini L, Ballabio A, Cosma MP (2007). SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. *Biochem J* **403:** 305-312.

Fraldi A, Hemsley KM, Sutherland L, Crawley A, Auricchio A, Ballabio A, Hopwood JJ (2006). AAV-mediated delivery of sulfamidase and SUMF1 genes to the brain of MPS-IIIA mice: a therapeutic strategy for MPS-IIIA. In: *9th International Symposium on Mucopolysaccharide and Related Diseases*: Venice, Italy, pp 64.

Franklin R, Quick M, Haase G (1999). Adenoviral vectors for in vivo gene delivery to oligodendrocytes: transgene expression and cytopathic consequences. *Gene Ther* **6:** 1360-7.

Fraser J, Gason AA, Wraith JE, Delatycki MB (2005). Sleep disturbance in Sanfilippo syndrome: a parental questionnaire study. *Arch Dis Child* **90:** 1239-42.

Fratantoni JC, Hall CW, Neufeld EF (1968). Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. *Science* **162:** 570-2.

Fratantoni JC, Hall CW, Neufeld EF (1969). The defect in Hurler and Hunter syndromes. II. Deficiency of specific factors involved in mucopolysaccharide degradation. *Proc Natl Acad Sci U S A* **64:** 360-6.

Frick KM, Burlingame LA, Arters JA, Berger-Sweeney J (2000). Reference memory, anxiety and estrous cyclicity in C57BL/6NIA mice are affected by age and sex. *Neuroscience* **95:** 293-307.

Frisella WA, O'Connor LH, Vogler CA, Roberts M, Walkley S, Levy B, Daly TM, Sands MS (2001). Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. *Mol Ther* **3:** 351-8.

Friso A, Tomanin R, Alba S, Gasparotto N, Puicher EP, Fusco M, Hortelano G, Muenzer J, Marin O, Zacchello F, Scarpa M (2005). Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. *J Gene Med* **7:** 1482-91.

Fu H, Kang L, Jennings JS, Moy SS, Perez A, Dirosario J, McCarty DM, Muenzer J (2007). Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. *Gene Ther***:** doi: 10.1038/sj.gt.3302961.

Fu H, Samulski, R. J., McCown, T. J., Picornell, Y. J., Fletcher, D., and Muenzer, J. (2002). Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. *Mol Ther* **5:** 42-49.

Fukuhara Y, Li XK, Kitazawa Y, Inagaki M, Matsuoka K, Kosuga M, Kosaki R, Shimazaki T, Endo H, Umezawa A, Okano H, Takahashi T, Okuyama T (2006). Histopathological and Behavioral Improvement of Murine Mucopolysaccharidosis Type VII by Intracerebral Transplantation of Neural Stem Cells. *Mol Ther* **13:** 548-55.

Fuller M, Rozaklis T, Ramsay SL, Hopwood JJ, Meikle PJ (2004). Disease-specific markers for the mucopolysaccharidoses. *Pediatr Res* **56:** 733-8.

Gabrielli O, Coppa GV, Bruni S, Villani GR, Pontarelli G, Di Natale P (2005). An adult Sanfilippo type A patient with homozygous mutation R206P in the sulfamidase gene. *Am J Med Genet A* **133:** 85-9.

Gaggar A, Shayakhmetov DM, Lieber A (2003). CD46 is a cellular receptor for group B adenoviruses. *Nat Med* **9:** 1408-12.

Gambotto A, Dworacki G, Cicinnati V, Kenniston T, Steitz J, Tuting T, Robbins PD, DeLeo AB (2000). Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. *Gene Ther* **7:** 2036-40.

Garbuzova-Davis S, Gografe SJ, Sanberg CD, Willing AE, Saporta S, Cameron DF, Desjarlais T, Daily J, Kuzmin-Nichols N, Chamizo W, Klasko SK, Sanberg PR (2006). Maternal transplantation of human umbilical cord blood cells provides prenatal therapy in Sanfilippo type B mouse model. *FASEB J* **20:** 485-7.

Garcia-Verdugo J, Ferron S, Flames N, Collado L, Desfilis E, Font E (2002). The proliferative ventricular zone in adult vertebrates: A comparative study using reptiles, birds, and mammals. *Brain Res Bull* **57:** 765-775.

Gelb MH, Turecek F, Scott CR, Chamoles NA (2006). Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. *J Inherit Metab Dis* **29:** 397-404.

Gerdes CA, Castro MG, Lowenstein PR (2000). Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. *Mol Ther* **2:** 330-8.

Gerlai RT, McNamara A, Williams S, Phillips HS (2002). Hippocampal dysfunction and behavioral deficit in the water maze in mice: an unresolved issue? *Brain Res Bull* **57:** 3-9.

German DC, Liang CL, Song T, Yazdani U, Xie C, Dietschy JM (2002). Neurodegeneration in the Niemann-Pick C mouse: glial involvement. *Neuroscience* **109:** 437-50.

Ghersi-Egea JF, Finnegan W, Chen JL, Fenstermacher JD (1996). Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. *Neuroscience* **75:** 1271-88.

Ghodsi A, Stein C, Derksen T, Martins I, Anderson RD, Davidson BL (1999). Systemic hyperosmolality improves beta-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer. *Exp Neurol* **160:** 109-116.

Ghodsi A, Stein C, Derksen T, Yang GY, Anderson RD, Davidson BL (1998). Extensive Beta-Glucuronidase Activity in Murine Central Nervous System after Adenovirus-Mediated Gene Transfer to Brain. *Hum Gene Ther* **9:** 2331-2340.

Gibbs DA, Spellacy E, Tompkins R, Watts RW, Mowbray JF (1983). A clinical trial of fibroblast transplantation for the treatment of mucopolysaccharidoses. *J Inherit Metab Dis* **6:** 62-81.

Giger U, Shivaprasad H, Wang P, Jezyk P, Patterson D, Bradley G (1997). Mucopolysaccharidosis type IIIB (Sanfilippo B syndrome) in emus [Abstract]. *Vet Pathol* **34**.

Gijtenbeek JM, van den Bent MJ, Vecht CJ (1999). Cyclosporine neurotoxicity: a review. *J Neurol* **246:** 339-46.

Ginsberg SD, Galvin JE, Lee VM, Rorke LB, Dickson DW, Wolfe JH, Jones MZ, Trojanowski JQ (1999). Accumulation of intracellular amyloid-beta peptide (A beta 1-40) in mucopolysaccharidosis brains. *J Neuropathol Exp Neurol* **58:** 815-24.

Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M (2006). Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. *Haematologica* **91:** 703-6.

Givogri MI, Galbiati F, Fasano S, Amadio S, Perani L, Superchi D, Morana P, Del Carro U, Marchesini S, Brambilla R, Wrabetz L, Bongarzone E (2006). Oligodendroglial progenitor cell therapy limits central neurological deficits in mice with metachromatic leukodystrophy. *J Neurosci* **26:** 3109-19.

Gliddon BL (2002). Enzyme Replacement Therapy in a Murine Model of Mucopolysaccharidosis Type IIIA [PhD Thesis]. University of Adelaide.

Gliddon BL, Hopwood JJ (2004). Enzyme-Replacement Therapy from Birth Delays the Development of Behavior and Learning Problems in Mucopolysaccharidosis Type IIIA Mice. *Pediatr Res* **56:** 65-72.

Gliddon BL, Yogalingam G, Hopwood JJ (2004). Purification and characterization of recombinant murine sulfamidase. *Mol Genet Metab* **83:** 239-45.

Glover CP, Bienemann AS, Hopton M, Harding TC, Kew JN, Uney JB (2003). Long-term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron-specific promoters are used. *J Gene Med* **5:** 554-9.

Goff SP (2001). Retroviridae: The Retroviruses and Their Replication. In: *Fundamental Virology*. Knipe DM, Howley PM, (eds). Lippincott Williams & Wilkins: Philadelphia, pp 843-912.

Goncalves MA, de Vries AA (2006). Adenovirus: from foe to friend. *Rev Med Virol* **16:** 167-86.

Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO (1995). Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. *Ann Intern Med* **122:** 33-9.

Greber UF, Suomalainen M, Stidwill RP, Boucke K, Ebersold MW, Helenius A (1997). The role of the nuclear pore complex in adenovirus DNA entry. *EMBO J* **16:** 5998-6007.

Greber UF, Willetts M, Webster P, Helenius A (1993). Stepwise dismantling of adenovirus 2 during entry into cells. *Cell* **75:** 477-86.

Griffiths G, Hoflack B, Simons K, Mellman I, Kornfeld S (1988). The mannose 6-phosphate receptor and the biogenesis of lysosomes. *Cell* **52:** 329-41.

Guida JD, Fejer G, Pirofski LA, Brosnan CF, Horwitz MS (1995). Mouse adenovirus type 1 causes a fatal hemorrhagic encephalomyelitis in adult C57BL/6 but not BALB/c mice. *J Virol* **69:** 7674-81.

Guidotti JE, Mignon A, Haase G, Caillaud C, McDonell N, Kahn A, Poenaru L (1999). Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-deficient knock-out mice. *Hum Mol Genet* **8:** 831-8.

Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. *N Engl J Med* **346:** 1185-93.

Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A (2003a). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. *N Engl J Med* **348:** 255-6.

Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D,

Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M (2003b). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science* **302:** 415-9.

Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML (1997). Construction of adenovirus vectors through Cre-lox recombination. *J Virol* **71:** 1842-9.

Harkness JE, Wagner JE (1995). The Biology and Medicine of Rabbits and Rodents. Cann C, (ed). Williams and Wilkins: Baltimore.

Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Yu ZF, Wittes J, Berger KI, Newman MS, Lowe AM, Kakkis E, Swiedler SJ (2006). Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. *J Pediatr* **148:** 533-539.

Hartung SD, Frandsen JL, Pan D, Koniar BL, Graupman P, Gunther R, Low WC, Whitley CB, McIvor RS (2004). Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. *Mol Ther* **9:** 866-75.

Harvey BG, Hackett NR, El-Sawy T, Rosengart TK, Hirschowitz EA, Lieberman MD, Lesser ML, Crystal RG (1999). Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. *J Virol* **73:** 6729-42.

Hasilik A (1992). The early and late processing of lysosomal enzymes: proteolysis and compartmentation. *Experientia* **48:** 130-51.

Haskins ME (2007). Animal models for mucopolysaccharidosis disorders and their clinical relevance. *Acta Paediatr Suppl* **96:** 56-62.

Hawkes C, Kar S (2004). The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system. *Brain Res Brain Res Rev* **44:** 117-40.

He T-C (2004). Vectors for Gene Therapy. In: *Current Protocols in Human Genetics*. Miranker L, (ed). John Wiley & Sons, Inc: Somerset.

Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA (2004). alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. *J Mol Biol* **338:** 453-62.

Hemsley KM, Hopwood JJ (2005). Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA). *Behav Brain Res* **158:** 191-9.

Hemsley KM, King B, Hopwood JJ (2007). Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. *Mol Genet Metab* **90:** 313-328.

Hemsley KM, Norman EJ, Crawley AC, Auclair D, King B, Fuller M, Zimmerman D, Meikle PJ, Jolly RD, Hopwood JJ (2006). CNS delivery of rhNS in the MPS IIIA Huntaway dog following cisternal injection. In: *9th International Symposium on Mucopolysaccharidide and Related Diseases*: Venice, Italy.

Hennig AK, Levy B, Ogilvie JM, Vogler CA, Galvin N, Bassnett S, Sands MS (2003). Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. *J Neurosci* **23:** 3302-3307.

Hennig AK, Ogilvie JM, Ohlemiller KK, Timmers AM, Hauswirth WW, Sands MS (2004). AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. *Mol Ther* **10:** 106-16.

Hernandez-Guzman FG, Higashiyama T, Pangborn W, Osawa Y, Ghosh D (2003). Structure of human estrone sulfatase suggests functional roles of membrane association. *J Biol Chem* **278:** 22989-97.

Hess B, Saftig P, Hartmann D, Coenen R, Lullmann-Rauch R, Goebel HH, Evers M, von Figura K, D'Hooge R, Nagels G, De Deyn P, Peters C, Gieselmann V (1996). Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. *Proc Natl Acad Sci U S A* **93:** 14821-6.

Heuer GG, Passini MA, Jiang K, Parente MK, Lee VM-Y, Trojanowski JQ, Wolfe JH (2002). Selective Neurodegeneration in Murine Mucopolysaccharidosis VII Is Progressive and Reversible. *Ann Neurol* **52:** 762-770.

Hobbs JR, Hugh Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, James DCO, Lucas CF, Rogers TR (1982). Reversal of Clinical Features of Hurler's Disease and Biochemical Improvement after Treatment by Bone Marrow Transplantation. *J Inherit Metab Dis* **5:** 59-60.

Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, James DC, Lucas CF, Rogers TR, Benson PF, Tansley LR, Patrick AD, Mossman J, Young EP (1981). Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. *Lancet* **2:** 709-12.

Hoflack B, Kornfeld S (1985). Purification and characterization of a cation-dependent mannose 6-phosphate receptor from murine P388D1 macrophages and bovine liver. *J Biol Chem* **260:** 12008-14.

Hofling AA, Devine S, Vogler C, Sands MS (2004). Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. *Mol Ther* **9:** 856-65.

Hofmann C, Loser P, Cichon G, Arnold W, Both GW, Strauss M (1999). Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. *J Virol* **73:** 6930-6.

Hogg S (1996). A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. *Pharmacol Biochem Behav* **54:** 21-30.

Honda T, Saitoh H, Masuko M, Katagiri-Abe T, Tominaga K, Kozakai I, Kobayashi K, Kumanishi T, Watanabe YG, Odani S, Kuwano R (2000). The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain. *Brain Res Mol Brain Res* **77:** 19-28.

Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, O'Meara A, Cornu G, Souillet G, Frappaz D, et al. (1995). Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. *Lancet* **345:** 1398-402.

Hoogerbrugge PM, Poorthuis BJ, Romme AE, van de Kamp JJ, Wagemaker G, van Bekkum DW (1988). Effect of bone marrow transplantation on enzyme levels and clinical course in the neurologically affected twitcher mouse. *J Clin Invest* **81:** 1790-4.

Hopwood JJ (1989). Enzymes that degrade heparin and heparan sulphate. In: *Heparin: Chemical and Biological Properties, Clinical Applications*. Lane DW, Lindahieds U, (eds). Edward Arnold: London, pp 190-229.

Hopwood JJ (2005). Prenatal diagnosis of Sanfilippo syndrome. *Prenat Diagn* **25:** 148-50.

Hopwood JJ, Ballabio A (2001). Multiple sulfatase deficiency and the nature of the sulfatase family. In: *The Metabolic and Molecular Basis of Inherited Disease*. Scriver CR, (ed). McGraw-Hill: New York, pp 3725-3732.

Hopwood JJ, Brooks DA (1997). An introduction to the basic science and biology of the lysosome and storage disorders. In: *Organelle Diseases*. Appelgarth DA, (ed). Chapman and Hall Medical: London, pp 7-35.

Hopwood JJ, Elliott H (1981). Sulphamidase activity in leucocytes, cultured skin fibroblasts and amniotic cells: diagnosis of the Sanfilippo A syndrome with the use of radiolabelled disaccharide substrate. *Clin Sci (Lond)* **61:** 729-35.

Hopwood JJ, Elliott H (1982). Diagnosis of Sanfilippo A syndrome by estimation of sulphamidase activity using a radiolabelled tetrasaccharide substrate. *Clin Chim Acta* **123:** 241-250.

Hopwood JJ, Harrison JR (1982). High-resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses. *Anal Biochem* **119:** 120-7.

Hopwood JJ, Morris CP (1990). The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment. *Mol Biol Med* **7:** 381-404.

Hotta Y, Honda T, Naito M, Kuwano R (2003). Developmental distribution of coxsackie virus and adenovirus receptor localized in the nervous system. *Brain Res Dev Brain Res* **143:** 1-13.

Hrebicek M, Mrazova L, Seyrantepe V, Durand S, Roslin NM, Noskova L, Hartmannova H, Ivanek R, Cizkova A, Poupetova H, Sikora J, Urinovska J, Stranecky V, Zeman J, Lepage P, Roquis D, Verner A, Ausseil J, Beesley CE, Maire I, Poorthuis BJ, van de Kamp J, van Diggelen OP, Wevers RA, Hudson TJ, Fujiwara TM, Majewski J, Morgan K, Kmoch S,

Pshezhetsky AV (2006). Mutations in TMEM76* cause mucopolysaccharidosis IIIC (Sanfilippo C syndrome). *Am J Hum Genet* **79:** 807-19.

Hurtado-Lorenzo A, David AL, Thomas CE, Castro MG, Lowenstein PR (2003). Use of Recombinant Adenovirus for Gene Transfer into the Rat Brain. In: *Viral Vectors for Gene Therapy*. Machida CA, (ed). Humana Press: Totowa, pp 113-133.

Hwu WL, Keutzer J, Chiang SC, Zhang X, Chien YH, Lee NC, Young S, Millington D, Fietz MJ (2006). Neonatal screening for Pompe disease: result from the Taiwan screening program. In: *The American Society of Human Genetics*: New Orleans, Louisiana.

Iacobelli-Martinez M, Nepomuceno RR, Connolly J, Nemerow GR (2005). CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines. *J Virol* **79:** 11259-68.

Iivonen H, Nurminen L, Harri M, Tanila H, Puolivali J (2003). Hypothermia in mice tested in Morris water maze. *Behav Brain Res* **141:** 207-13.

Ilan Y, Attavar P, Takahashi M, Davidson A, Horwitz MS, Guida J, Chowdhury NR, Chowdhury JR (1996). Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. *J Clin Invest* **98:** 2640-7.

Ilan Y, Prakash R, Davidson A, Jona, Droguett G, Horwitz MS, Chowdhury NR, Chowdhury JR (1997). Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. *J Clin Invest* **99:** 1098-106.

Ilan Y, Sauter B, Chowdhury NR, Reddy BV, Thummala NR, Droguett G, Davidson A, Ott M, Horwitz MS, Chowdhury JR (1998). Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. *Hepatology* **27:** 1368-76.

Imhof JT, Coelho ZM, Schmitt ML, Morato GS, Carobrez AP (1993). Influence of gender and age on performance of rats in the elevated plus maze apparatus. *Behav Brain Res* **56:** 177-80.

Jackson DA, Juranek S, Lipps HJ (2006). Designing Nonviral Vectors for Efficient Gene Transfer and Long-Term Gene Expression. *Mol Ther* **14:** 613-26.

Jalanko A, Tenhunen K, McKinney CE, LaMarca ME, Rapola J, Autti T, Joensuu R, Manninen T, Sipila I, Ikonen S, Riekkinen P, Jr., Ginns EI, Peltonen L (1998). Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients. *Hum Mol Genet* **7:** 265-72.

Jerebtsova M, Batshaw ML, Ye X (2002). Humoral immune response to recombinant adenovirus and adeno-associated virus after in utero administration of viral vectors in mice. *Pediatr Res* **52:** 95-104.

Jeyakumar M, Norflus F, Tifft CJ, Cortina-Borja M, Butters TD, Proia RL, Perry VH, Dwek RA, Platt FM (2001). Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. *Blood* **97:** 327-9.

Jolly RD, Allan FJ, Collett MG, Rozaklis T, Muller VJ, Hopwood JJ (2000). Mucopolysaccharidosis IIIA (Sanfilippo syndrome) in a New Zealand Huntaway dog with ataxia. *N Z Vet J* **48:** 144-148.

Jordan MC, Zheng Y, Ryazantsev S, Rozengurt N, Roos KP, Neufeld EF (2005). Cardiac manifestations in the mouse model of mucopolysaccharidosis I. *Mol Genet Metab* **86:** 233-43.

Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I (1998). Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. *Proc Natl Acad Sci U S A* **95:** 11377-82.

Kajiwara K, Byrnes AP, Ohmoto Y, Charlton HM, Wood MJ, Wood KJ (2000). Humoral immune responses to adenovirus vectors in the brain. *J Neuroimmunol* **103:** 8-15.

Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P, Mobley W, Dickson P, Hanson S, Passage M (2004). Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. *Mol Genet Metab* **83:** 163-74.

Kamata Y, Okuyama T, Kosuga M, O'Hira A, Kanaji A, Sasaki K, Yamada M, Azuma N (2001). Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII. *Mol Ther* **4:** 307-312.

Kamata Y, Tanabe A, Kanaji A, Kosuga M, Fukuhara Y, Li XK, Suzuki S, Yamada M, Azuma N, Okuyama T (2003). Long-term normalization in the central nervous system, ocular

manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII. *Gene Ther* **10:** 406-14.

Kanaji A, Kosuga M, Li XK, Fukuhara Y, Tanabe A, Kamata Y, Azuma N, Yamada M, Sakamaki T, Toyama Y, Okuyama T (2003). Improvement of skeletal lesions in mice with mucopolysaccharidosis type VII by neonatal adenoviral gene transfer. *Mol Ther* **8:** 718-25.

Karageorgos L, Hill B, Bawden MJ, Hopwood JJ (2007). Bovine Mucopolysaccharidosis type IIIB. *J Inherit Metab Dis***:** doi: 10.1007/s10545-007-0539-5.

Karageorgos LE, Guo X-H, Blanch L, Weber B, Anson DA, Scott HS, Hopwood JJ (1996). Structure and Sequence of the Human Sulphamidase Gene. *DNA Res* **3:** 269-271.

Karolewski BA, Wolfe JH (2006). Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. *Mol Ther*.

Karpati G, Lochmuller H, Nalbantoglu J, Durham H (1996). The principles of gene therapy for the nervous system. *Trends Neurosci* **19:** 49-54.

Karpova EA, Voznyi YV, Keulemans JLM, Hoogeveen AT, Winchester B, Tsvetkova IV, Vandiggelen OP (1996). A Fluorimetric Enzyme Assay for the Diagnosis of Sanfilippo Disease Type A (MPS IIIA). *J Inherit Metab Dis* **19:** 278-285.

Kasperzyk JL, d'Azzo A, Platt FM, Alroy J, Seyfried TN (2005). Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. *J Lipid Res* **46:** 744-51.

Kasperzyk JL, El-Abbadi MM, Hauser EC, D'Azzo A, Platt FM, Seyfried TN (2004). N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. *J Neurochem* **89:** 645-53.

Kawakami N, Sakane N, Nishizawa F, Iwao M, Fukada SI, Tsujikawa K, Kohama Y, Ikawa M, Okabe M, Yamamoto H (1999). Green fluorescent protein-transgenic mice: immune functions and their application to studies of lymphocyte development. *Immunol Lett* **70:** 165-71.

Keeling KM, Bedwell DM (2002). Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. *J Mol Med* **80:** 367-76.

Keriel A, Rene C, Galer C, Zabner J, Kremer EJ (2006). Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors. *J Virol* **80:** 1487-96.

Kim HY (2000). [Online, accessed 12 Aug, 2004] http://hykim.chungbuk.ac.kr/lectures/biomem/17/fig17-40.jpg

Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L (2001). Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. *Proc Natl Acad Sci U S A* **98:** 13282-7.

King B, Savas P, Fuller M, Hopwood J, Hemsley K (2006). Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA. *Mol Genet Metab* **87:** 107-12.

Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE (2007). Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. *Neurology* **68:** 99-109.

Kleijer WJ, Karpova EA, Geilen GC, Keulemans JLM, Huijmans JGM, Tsvetkova IV, Voznyi YV, Vandiggelen OP (1996). Prenatal Diagnosis of Sanfilippo a Syndrome - Experience in 35 Pregnancies at Risk and the Use of a New Fluorogenic Substrate for the Heparin Sulphamidase Assay. *Prenatal Diagnosis* **16:** 829-835.

Klein RL, Dayton RD, Leidenheimer NJ, Jansen K, Golde TE, Zweig RM (2006). Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. *Mol Ther* **13:** 517-27.

Klonjkowski B, Gilardi-Hebenstreit P, Hadchouel J, Randrianarison V, Boutin S, Yeh P, Perricaudet M, Kremer EJ (1997). A recombinant E1-deleted canine adenoviral vector

capable of transduction and expression of a transgene in human-derived cells and in vivo. *Hum Gene Ther* **8:** 2103-15.

Knudson AG, Jr., Di Ferrante N, Curtis JE (1971). Effect of leukocyte transfusion in a child with type II mucopolysaccharidosis. *Proc Natl Acad Sci U S A* **68:** 1738-41.

Kobayashi H, Carbonaro D, Pepper K, Petersen D, Ge S, Jackson H, Shimada H, Moats R, Kohn DB (2005). Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. *Mol Ther* **11:** 776-89.

Koehler DR, Martin B, Corey M, Palmer D, Ng P, Tanswell AK, Hu J (2006). Readministration of helper-dependent adenovirus to mouse lung. *Gene Ther* **13:** 773-80.

Kolls JK, Lei D, Odom G, Nelson S, Summer WR, Gerber MA, Shellito JE (1996). Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. *Hum Gene Ther* **7:** 489-97.

Konishi Y, Fushimi S, Shirabe T (2005). Immunohistochemical distribution of cation-dependent mannose 6-phosphate receptors in the mouse central nervous system: comparison with that of cation-independent mannose 6-phophate receptors. *Neurosci Lett* **378:** 7-12.

Kornfeld S (1992). Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. *Annu Rev Biochem* **61:** 307-30.

Kornfeld S, Mellman I (1989). The biogenesis of lysosomes. *Annu Rev Cell Biol* **5:** 483-525.

Kosuga M, Takahashi S, Sasaki K, Enosawa S, Li XK, Okuyama S, Fujino M, Suzuki S, Yamada M, Matsuo N, Sakuragawa N, Okuyama T (2000). Phenotype correction in murine mucopolysaccharidosis type VII by transplantation of human amniotic epithelial cells after adenovirus-mediated gene transfer. *Cell Transplant* **9:** 687-692.

Kosuga M, Takahashi S, Tanabe A, Fujino M, Li XK, Suzuki S, Yamada M, Kakishita K, Ono F, Sakuragawa N, Okuyama T (2001). Widespread distribution of adenovirus-transduced monkey amniotic epithelial cells after local intracerebral injection: Implication for cell-mediated therapy for lysosome storage disorders. *Cell Transplant* **10:** 435-439.

Kremer EJ, Boutin S, Chillon M, Danos O (2000). Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. *J Virol* **74:** 505-12.

Kresse H, Neufeld EF (1972). The Sanfilippo A corrective factor. Purification and mode of action. *J Biol Chem* **247:** 2164-70.

Kurai T, Hisayasu S, Kitagawa R, Migita M, Suzuki H, Hirai Y, Shimada T (2007). AAV1 Mediated Co-expression of Formylglycine-Generating Enzyme and Arylsulfatase A Efficiently Corrects Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy. *Mol Ther* **15:** 38-43.

Kuzmin AI, Finegold MJ, Eisensmith RC (1997). Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. *Gene Ther* **4:** 309-16.

Kuzmin AI, Galenko O, Eisensmith RC (2001). An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors. *Mol Ther* **3:** 293-301.

Lachmann RH, te Vruchte D, Lloyd-Evans E, Reinkensmeier G, Sillence DJ, Fernandez-Guillen L, Dwek RA, Butters TD, Cox TM, Platt FM (2004). Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. *Neurobiol Dis* **16:** 654-8.

Lamberty Y, Gower AJ (1996). Arm width and brightness modulation of spontaneous behaviour of two strains of mice tested in the elevated plus-maze. *Physiol Behav* **59:** 439-44.

Lange MC, Teive HA, Troiano AR, Bitencourt M, Funke VA, Setubal DC, Zanis Neto J, Medeiros CR, Werneck LC, Pasquini R, Bonfim CM (2006). Bone marrow transplantation in patients with storage diseases: a developing country experience. *Arq Neuropsiquiatr* **64:** 1-4.

Lau AA, Hemsley KM, Meedeniya A, Hopwood JJ (2004). In vitro characterization of genetically modified embryonic stem cells as a therapy for murine mucopolysaccharidosis type IIIA. *Mol Genet Metab* **81:** 86-95.

Lawler DF (1989). Care and Diseases of Neonatal Puppies and Kittens. In: *Current Veterinary Therapy (Small Animal Practice)*. Kirk RW, (ed). W. B. Saunders Company: Philadelphia, pp 1325-1334.

Lawrence MS, Foellmer HG, Elsworth JD, Kim JH, Leranth C, Kozlowski DA, Bothwell AL, Davidson BL, Bohn MC, Redmond DE, Jr. (1999). Inflammatory responses and their impact on beta-galactosidase transgene expression following adenovirus vector delivery to the primate caudate nucleus. *Gene Ther* **6:** 1368-79.

Lechner RL, Kelly TJ, Jr. (1977). The structure of replicating adenovirus 2 DNA molecules. *Cell* **12:** 1007-20.

Lee-Chen GJ, Lin SP, Ko MH, Chuang CK, Chen CP, Lee HH, Cheng SC, Shen CH, Tseng KL, Li CL (2002). Identification and characterization of mutations underlying Sanfilippo syndrome type A (mucopolysaccharidosis type IIIA). *Clin Genet* **61:** 192-7.

Leppard KN (1997). E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. *J Gen Virol* **78 (Pt 9):** 2131-8.

Lessard MD, Alley TL, Proctor JL, Levy B, Galvin N, Vogler CA, Soper BW (2006). Attenuation of murine lysosomal storage disease by allogeneic neonatal bone marrow transplantation using costimulatory blockade and donor lymphocyte infusion without myeloablation. *Clin Immunol* **119:** 166-79.

Lewinsohn PM, Gotlib IH, Lewinsohn M, Seeley JR, Allen NB (1998). Gender differences in anxiety disorders and anxiety symptoms in adolescents. *J Abnorm Psychol* **107:** 109-17.

Li E, Stupack D, Bokoch GM, Nemerow GR (1998a). Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. *J Virol* **72:** 8806-12.

Li E, Stupack D, Klemke R, Cheresh DA, Nemerow GR (1998b). Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH kinase. *J Virol* **72:** 2055-61.

Li HH, Yu WH, Rozengurt N, Zhao HZ, Lyons KM, Anagnostaras S, Fanselow MS, Suzuki K, Vanier MT, Neufeld EF (1999). Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. *Proc Natl Acad Sci U S A* **96:** 14505-14510.

Li HH, Zhao HZ, Neufeld EF, Cai Y, Gomez-Pinilla F (2002). Attenuated plasticity in neurons and astrocytes in the mouse model of Sanfilippo syndrome type B. *J Neurosci Res* **69:** 30-38.

Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F, Gelb MH (2004). Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. *Clin Chem* **50:** 1785-96.

Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. *Psychopharmacology (Berl)* **92:** 180-5.

Liu G, Chen YH, He X, Martins I, Heth JA, Chiorini JA, Davidson BL (2007). Adeno-associated Virus Type 5 Reduces Learning Deficits and Restores Glutamate Receptor Subunit Levels in MPS VII Mice CNS. *Mol Ther* **15:** 242-7.

Liu G, Martins I, Wemmie JA, Chiorini JA, Davidson BL (2005a). Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. *J Neurosci* **25:** 9321-7.

Liu HS, Jan MS, Chou CK, Chen PH, Ke NJ (1999). Is green fluorescent protein toxic to the living cells? *Biochem Biophys Res Commun* **260:** 712-7.

Liu J, Thorp SC (2002). Cell surface heparan sulfate and its roles in assisting viral infections. *Med Res Rev* **22:** 1-25.

Liu Y, Xu L, Hennig AK, Kovacs A, Fu A, Chung S, Lee D, Wang B, Herati RS, Mosinger Ogilvie J, Cai SR, Parker Ponder K (2005b). Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. *Mol Ther* **11:** 35-47.

Lochmuller H, Petrof BJ, Allen C, Prescott S, Massie B, Karpati G (1995). Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. *Biochem Biophys Res Commun* **213:** 569-74.

Logue SF, Paylor R, Wehner JM (1997). Hippocampal lesions cause learning deficits in inbred mice in the Morris water maze and conditioned-fear task. *Behav Neurosci* **111:** 104-13.

Lois C, Alvarez-Buylla A (1994). Long-distance neuronal migration in the adult mammalian brain. *Science* **264:** 1145-8.

Loser P, Hofmann C, Both GW, Uckert W, Hillgenberg M (2003). Construction, rescue, and characterization of vectors derived from ovine atadenovirus. *J Virol* **77:** 11941-51.

Lowry RB, Applegarth DA, Toone JR, MacDonald E, Thunem NY (1990). An update on the frequency of mucopolysaccharide syndromes in British Columbia. *Hum Genet* **85:** 389-90.

Lukatela G, Krauss N, Theis K, Selmer T, Gieselmann V, von Figura K, Saenger W (1998). Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. *Biochemistry* **37:** 3654-64.

Luo D, Saltzman WM (2000). Synthetic DNA delivery systems. *Nat Biotechnol* **18:** 33-7.

Lutz P, Kedinger C (1996). Properties of the adenovirus IVa2 gene product, an effector of late-phase-dependent activation of the major late promoter. *J Virol* **70:** 1396-405.

Lutz P, Rosa-Calatrava M, Kedinger C (1997). The product of the adenovirus intermediate gene IX is a transcriptional activator. *J Virol* **71:** 5102-9.

Lutzko C, Omori F, Abrams-Ogg ACG, Shull R, Li LH, Lau K, Ruedy C, Nanji S, Gartley C, Dobson H, Foster R, Kruth S, Dube ID (1999). Gene therapy for canine alpha-L-iduronidase deficiency: In utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. *Hum Gene Ther* **10:** 1521-1532.

Ma X, Liu Y, Tittiger M, Hennig A, Kovacs A, Popelka S, Wang B, Herati R, Bigg M, Ponder KP (2007). Improvements in Mucopolysaccharidosis I Mice After Adult Retroviral Vector-mediated Gene Therapy with Immunomodulation. *Mol Ther***:** doi:10.1038/sj.mt.6300112.

Macri S, Adriani W, Chiarotti F, Laviola G (2002). Risk taking during exploration of a plus-maze is greater in adolescent than in juvenile or adult mice. *Animal Behaviour* **64:** 541-546.

Malatack JJ, Consolini DM, Bayever E (2003). The status of hematopoietic stem cell transplantation in lysosomal storage disease. *Pediatr Neurol* **29:** 391-403.

Mango RL, Xu L, Sands MS, Vogler C, Seiler G, Schwarz T, Haskins ME, Ponder KP (2004). Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. *Mol Genet Metab* **82:** 4-19.

Martin JJ, Ceuterick C, Van Dessel G, Lagrou A, Dierick W (1979). Two cases of mucopolysaccharidosis type III (Sanfilippo). An anatomopathological study. *Acta Neuropathol (Berl)* **46:** 185-90.

Martin PL, Carter SL, Kernan NA, Sahdev I, Wall D, Pietryga D, Wagner JE, Kurtzberg J (2006). Results of the cord blood transplantation study (COBLT): outcomes of unrelated

donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. *Biol Blood Marrow Transplant* **12:** 184-94.

Martin-Touaux E, Puech JP, Chateau D, Emiliani C, Kremer EJ, Raben N, Tancini B, Orlacchio A, Kahn A, Poenaru L (2002). Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy. *Hum Mol Genet* **11:** 1637-45.

Mason KE, Meikle PJ, Hopwood JJ, Fuller M (2006). Characterization of sulfated oligosaccharides in mucopolysaccharidosis type IIIA by electrospray ionization mass spectrometry. *Anal Chem* **78:** 4534-42.

Mastakov MY, Baer K, Symes CW, Leichtlein CB, Kotin RM, During MJ (2002). Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. *J Virol* **76:** 8446-8454.

Matsuda J, Suzuki O, Oshima A, Yamamoto Y, Noguchi A, Takimoto K, Itoh M, Matsuzaki Y, Yasuda Y, Ogawa S, Sakata Y, Nanba E, Higaki K, Ogawa Y, Tominaga L, Ohno K, Iwasaki H, Watanabe H, Brady RO, Suzuki Y (2003). Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. *Proc Natl Acad Sci U S A* **100:** 15912-7.

Mazzolini G, Narvaiza I, Perez-Diez A, Rodriguez-Calvillo M, Qian C, Sangro B, Ruiz J, Prieto J, Melero I (2001). Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. *Gene Ther* **8:** 259-67.

McClelland JL, McNaughton BL, O'Reilly RC (1995). Why there are complementary learning systems in the hippocampus and neocortex: insights from the successes and failures of connectionist models of learning and memory. *Psychol Rev* **102:** 419-57.

McCown TJ (2005). Adeno-associated virus (AAV) vectors in the CNS. *Curr Gene Ther* **5:** 333-8.

McGlynn R, Dobrenis K, Walkley SU (2004). Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. *J Comp Neurol* **480:** 415-26.

McIlwain KL, Merriweather MY, Yuva-Paylor LA, Paylor R (2001). The use of behavioral test batteries: effects of training history. *Physiol Behav* **73:** 705-17.

McKenna JT, Vertes RP (2004). Afferent projections to nucleus reuniens of the thalamus. *J Comp Neurol* **480:** 115-42.

McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J, Shera D, Lioutermann L, Feely M, Freese A, Leone P (2006). Immune responses to AAV in a phase I study for Canavan disease. *J Gene Med* **8:** 577-88.

Medina-Kauwe LK (2003). Endocytosis of adenovirus and adenovirus capsid proteins. *Adv Drug Deliv Rev* **55:** 1485-96.

Meertens L, Zhao Y, Rosic-Kablar S, Li L, Chan K, Dobson H, Gartley C, Lutzko C, Hopwood J, Kohn D, Kruth S, Hough MR, Dube ID (2002). In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression. *Hum Gene Ther* **13:** 1809-20.

Meier O, Boucke K, Hammer SV, Keller S, Stidwill RP, Hemmi S, Greber UF (2002). Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. *J Cell Biol* **158:** 1119-31.

Meier O, Greber UF (2004). Adenovirus endocytosis. *J Gene Med* **6 Suppl 1:** S152-63.

Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, Fietz MJ, Simonsen H, Fuller M, Brooks DA, Hopwood JJ (2006). Newborn screening for lysosomal storage disorders. *Mol Genet Metab* **88:** 307-14.

Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999). Prevalence of Lysosomal Storage Disorders. *JAMA* **281:** 249-254.

Meng XL, Shen JS, Ohashi T, Maeda H, Kim SU, Eto Y (2003). Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. *J Neurosci Res* **74:** 266-77.

Mian A, Guenther M, Finegold M, Ng P, Rodgers J, Lee B (2005). Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors. *Mol Genet Metab* **84:** 278-88.

Michou AI, Lehrmann H, Saltik M, Cotten M (1999). Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors. *J Virol* **73:** 1399-410.

Michou AI, Santoro L, Christ M, Julliard V, Pavirani A, Mehtali M (1997). Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. *Gene Ther* **4:** 473-82.

Mittal SK, Prevec L, Graham FL, Babiuk LA (1995). Development of a bovine adenovirus type 3-based expression vector. *J Gen Virol* **76 (Pt 1):** 93-102.

Mittereder N, March KL, Trapnell BC (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. *J Virol* **70:** 7498-509.

Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T (2000). IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. *Mol Ther* **1:** 376-82.

Mok H, Palmer DJ, Ng P, Barry MA (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. *Mol Ther* **11:** 66-79.

Montfort M, Garrido E, Hopwood JJ, Grinberg D, Chabas A, Vilageliu L (2004). Expression and functional characterization of human mutant sulfamidase in insect cells. *Mol Genet Metab* **83:** 246-51.

Montfort M, Vilageliu L, Garciagiralt N, Guidi S, Coll MJ, Chabas A, Grinberg D (1998). Mutation 1091delC Is Highly Prevalent in Spanish Sanfilippo Syndrome Type A Patients. *Hum Mutat* **12:** 274-279.

Morral N, Parks RJ, Zhou H, Langston C, Schiedner G, Quinones J, Graham FL, Kochanek S, Beaudet AL (1998). High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. *Hum Gene Ther* **9:** 2709-16.

Muenzer J, Neufeld EF, Constantopoulos G, Caruso RC, Kaiser-Kupfer MI, Pikus A, Danoff J, Berry RR, McDonald HD, Thompson JN, et al. (1992). Attempted enzyme replacement using human amnion membrane implantations in mucopolysaccharidoses. *J Inherit Metab Dis* **15:** 25-37.

Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga AC, Ulbrich B,

Shinawi M, Cleary M, Piper D, Conway AM, Kimura A (2006). A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). *Genet Med* **8:** 465-73.

Mullins C, Bonifacino JS (2001). The molecular machinery for lysosome biogenesis. *Bioessays* **23:** 333-43.

Munoz MVR, Dickson P, Vieira TA, Costa R, Vedolin L, Canani S, Jardim L, Raymundo MM, Kakkis E, Giugliani R (2006). CSF GAG behaviour during intra-thecal enzyme replacement therapy in a patient with MPS I and spinal cord compression. In: *9th International Symposium on Mucopolysaccharide and Related Diseases*: Venice, Italy, pp 55.

Murer EH, Levin J, Holme R (1975). Isolation and studies of the granules of the amebocytes of Limulus polyphemus, the horseshoe crab. *J Cell Physiol* **86:** 533-42.

Muschol N, Storch S, Ballhausen D, Beesley C, Westermann JC, Gal A, Ullrich K, Hopwood JJ, Winchester B, Braulke T (2004). Transport, enzymatic activity, and stability of mutant sulfamidase (SGSH) identified in patients with mucopolysaccharidosis type III A. *Hum Mutat* **23:** 559-66.

Nadon NL, Draeger K (1996). Genomic DNA analysis from mouse toe lysates. *Transgenic Res* **5:** 209-11.

Nagaeva DV, Akhmadeev AV (2006). Structural organization, neurochemical characteristics, and connections of the reticular nucleus of the thalamus. *Neurosci Behav Physiol* **36:** 987-95.

Natowicz MR, Short MP, Wang Y, Dickersin GR, Gebhardt MC, Rosenthal DI, Sims KB, Rosenberg AE (1996). Clinical and biochemical manifestations of hyaluronidase deficiency. *N Engl J Med* **335:** 1029-33.

Nelson J (1997). Incidence of the mucopolysaccharidoses in Northern Ireland. *Hum Genet* **101:** 355-8.

Neufeld EF, Muenzer J (2001). The Mucopolysaccharidoses. In: *The Metabolic and Molecular Bases of Inherited Diseases*. Scriver CR, (ed). McGraw-Hill: New York, pp 3421-3452.

Ni X, Morales CR (2006). The lysosomal trafficking of acid sphingomyelinase is mediated by sortilin and mannose 6-phosphate receptor. *Traffic* **7:** 889-902.

Nicklin SA, Wu E, Nemerow GR, Baker AH (2005). The influence of adenovirus fiber structure and function on vector development for gene therapy. *Mol Ther* **12:** 384-93.

Nicolino MP, Puech JP, Kremer EJ, Reuser AJ, Mbebi C, Verdiere-Sahuque M, Kahn A, Poenaru L (1998). Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation. *Hum Mol Genet* **7:** 1695-702.

Nidiffer FD, Kelly TE (1983). Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: an epidemiological study. *J Ment Defic Res* **27 (Pt 3):** 185-203.

Niswender KD, Blackman SM, Rohde L, Magnuson MA, Piston DW (1995). Quantitative imaging of green fluorescent protein in cultured cells: comparison of microscopic techniques, use in fusion proteins and detection limits. *J Microsc* **180:** 109-16.

Norflus F, Tifft CJ, McDonald MP, Goldstein G, Crawley JN, Hoffmann A, Sandhoff K, Suzuki K, Proia RL (1998). Bone Marrow Transplantation Prolongs Life Span and Ameliorates Neurologic Manifestations in Sandhoff Disease Mice. *J Clin Invest* **101:** 1881-1888.

O'Connor LH, Erway LC, Vogler CA, Sly WS, Nicholes A, Grubb J, Holmberg SW, Levy B, Sands MS (1998). Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. *J Clin Invest* **101:** 1394-400.

Ohashi T, Watabe K, Uehara K, Sly WS, Vogler C, Eto Y (1997). Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. *Proc Natl Acad Sci U S A* **94:** 1287-92.

Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF (2003). Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. *Proc Natl Acad Sci U S A* **100:** 1902-7.

Ohmoto Y, Wood MJ, Charlton HM, Kajiwara K, Perry VH, Wood KJ (1999). Variation in the immune response to adenoviral vectors in the brain: influence of mouse strain, environmental conditions and priming. *Gene Ther* **6:** 471-81.

Okada T, Nomoto T, Yoshioka T, Nonaka-Sarukawa M, Ito T, Ogura T, Iwata-Okada M, Uchibori R, Shimazaki K, Mizukami H, Kume A, Ozawa K (2005). Large-scale production of recombinant viruses by use of a large culture vessel with active gassing. *Hum Gene Ther* **16:** 1212-8.

Okumiya T, Kroos MA, Vliet LV, Takeuchi H, Van der Ploeg AT, Reuser AJ (2007). Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. *Mol Genet Metab* **90:** 49-57.

Oldfors A, Sourander P (1981). Storage of lipofuscin in neurons in mucopolysaccharidosis. Report on a case of Sanfilippo's syndrome with histochemical and electron-microscopic findings. *Acta Neuropathol (Berl)* **54:** 287-92.

O'Neal WK, Zhou H, Morral N, Langston C, Parks RJ, Graham FL, Kochanek S, Beaudet AL (2000). Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. *Mol Med* **6:** 179-95.

O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE (1999). PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. *Hum Gene Ther* **10:** 1349-58.

Palmer DJ, Ng P (2005). Helper-dependent adenoviral vectors for gene therapy. *Hum Gene Ther* **16:** 1-16.

Parish CR (2005). Heparan sulfate and inflammation. *Nat Immunol* **6:** 861-2.

Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL (1996). A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. *Proc Natl Acad Sci U S A* **93:** 13565-70.

Passini MA, Lee EB, Heuer GG, Wolfe JH (2002). Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. *J Neurosci* **22:** 6437-6446.

Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH (2003). Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. *J Virol* **77:** 7034-40.

Paul CA, Reid PC, Boegle AK, Karten B, Zhang M, Jiang ZG, Franz D, Lin L, Chang TY, Vance JE, Blanchette-Mackie J, Maue RA (2005). Adenovirus expressing an NPC1-GFP fusion gene corrects neuronal and nonneuronal defects associated with Niemann pick type C disease. *J Neurosci Res* **81:** 706-19.

Pauly DF, Fraites TJ, Toma C, Bayes HS, Huie ML, Hirschhorn R, Plotz PH, Raben N, Kessler PD, Byrne BJ (2001). Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease. *Hum Gene Ther* **12:** 527-38.

Paxinos G, Franklin KBJ (2001). *The Mouse Brain in Stereotaxic Coordinates*, 2nd edn. Academic Press: San Diego.

Pedrini V, Lennzi L, Zambotti V (1962). Isolation and identification of keratosulphate in urine of patients affected by Morquio-Ullrich disease. *Proc Soc Exp Biol Med* **110:** 847-9.

Pellow S, Chopin P, File SE, Briley M (1985). Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. *J Neurosci Methods* **14:** 149-67.

Peltekian E, Garcia L, Danos O (2002). Neurotropism and retrograde axonal transport of a canine adenoviral vector: a tool for targeting key structures undergoing neurodegenerative processes. *Mol Ther* **5:** 25-32.

Peltekian E, Parrish E, Bouchard C, Peschanski M, Lisovoski F (1997). Adenovirus-mediated gene transfer to the brain: methodological assessment. *J Neurosci Methods* **71:** 77-84.

Peltola M, Kyttala A, Heinonen O, Rapola J, Paunio T, Revah F, Peltonen L, Jalanko A (1998). Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse. *Gene Ther* **5:** 1314-21.

Peng Y, Falck-Pedersen E, Elkon KB (2001). Variation in adenovirus transgene expression between BALB/c and C57BL/6 mice is associated with differences in interleukin-12 and gamma interferon production and NK cell activation. *J Virol* **75:** 4540-50.

Peng Z (2004). The genesis of Gendicine:The story behind the first gene therapy. *BioPharm International* **17:** 42-49.

Perkins KJ, Byers S, Yogalingam G, Weber B, Hopwood JJ (1999). Expression and Characterization of Wild Type and Mutant Recombinant Human Sulfamidase. *J Biol Chem* **274:** 37193-37199.

Perkins KJ, Muller V, Weber B, Hopwood JJ (2001). Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients. *Mol Genet Metab* **73:** 306-312.

Perreau M, Guerin M-C, McVey JH, Parker AL, Baker AH, Drouet C, Kremer EJ (submitted). The interaction of human plasma components with a xenogenic adenovirus: implications for immunogenic properties during gene therapy.

Perreau M, Kremer EJ (2005). Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. *J Virol* **79:** 14595-605.

Perreau M, Kremer EJ (2006). The conundrum between immunological memory to adenovirus and their use as vectors in clinical gene therapy. *Mol Biotechnol* **34:** 247-56.

Perreau M, Mennechet F, Serratrice N, Wodrich H, Kremer EJ (2007). Contrasting effects on the phenotypical and functional maturation of human dendritic cells by human, canine and hybrid adenovirus vectors: implication for clinical efficacy. *J Virol* **81:** 3272-3284.

Persson A, Fan X, Widegren B, Englund E (2006). Cell type- and region- dependent coxsackie adenovirus receptor expression in the central nervous system. *J Neurooncol* **78:** 1-6.

Petrof BJ, Acsadi G, Jani A, Massie B, Bourdon J, Matusiewicz N, Yang L, Lochmuller H, Karpati G (1995). Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. *Am J Respir Cell Mol Biol* **13:** 508-17.

Pfeifer A, Verma IM (2001). Viral vectors and their applications. In: *Fundamental Virology*. Knipe DM, Howley PM, (eds). Lippincott Williams & Wilkins: Philadelphia, pp 353-376.

Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, Pinto E, Silva E, Rocha S, Marcao A, Ribeiro I, Lacerda L, Ribeiro G, Amaral O, Sa Miranda MC (2004). Prevalence of lysosomal storage diseases in Portugal. *Eur J Hum Genet* **12:** 87-92.

Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, Wegrzyn A, Wegrzyn G (2006). Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. *Eur J Hum Genet* **14:** 846-52.

Ponder KP, Haskins M (2006). Gene therapy for Mucopolysaccharidosis. In: *9th International Symposium on Mucopolysaccharide and Related Diseases*: Venice, Italy, pp 59-60.

Ponder KP, Melniczek JR, Xu L, Weil MA, O'Malley TM, O'Donnell PA, Knox VW, Aguirre GD, Mazrier H, Ellinwood NM, Sleeper M, Maguire AM, Volk SW, Mango RL, Zweigle J, Wolfe JH, Haskins ME (2002). Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. *Proc Natl Acad Sci U S A* **99:** 13102-7.

Ponder KP, Wang B, Wang P, Ma X, Herati R, Cullen K, O'Donnell P, Ellinwood NM, Traas A, Primeau TM, Haskins ME (2006). Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. *Mol Ther* **14:** 5-13.

Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP (1999). The frequency of lysosomal storage diseases in The Netherlands. *Hum Genet* **105:** 151-156.

Prows CA, Sanchez N, Daugherty C, Grabowski GA (1997). Gaucher disease: enzyme therapy in the acute neuronopathic variant. *Am J Med Genet* **71:** 16-21.

Przybylska M, Wu IH, Zhao H, Ziegler RJ, Tousignant JD, Desnick RJ, Scheule RK, Cheng SH, Yew NS (2004). Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors. *J Gene Med* **6:** 85-92.

Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. *Mol Genet Metab* **80:** 148-58.

Rauch SL, Shin LM, Wright CI (2003). Neuroimaging studies of amygdala function in anxiety disorders. *Ann N Y Acad Sci* **985:** 389-410.

Reddy PS, Idamakanti N, Hyun BH, Tikoo SK, Babiuk LA (1999). Development of porcine adenovirus-3 as an expression vector. *J Gen Virol* **80 (Pt 3):** 563-70.

Rees S, Coote J, Stables J, Goodson S, Harris S, Lee MG (1996). Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. *Biotechniques* **20:** 102-4, 106, 108-10.

Regardsoe EL, McMenamin MM, Charlton HM, Wood MJ (2004). Local adenoviral expression of Fas ligand upregulates pro-inflammatory immune responses in the CNS. *Gene Ther* **11:** 1462-74.

Reitman ML, Varki A, Kornfeld S (1981). Fibroblasts from patients with I-cell disease and pseudo-Hurler polydystrophy are deficient in uridine 5'-diphosphate-N-acetylglucosamine: glycoprotein N-acetylglucosaminylphosphotransferase activity. *J Clin Invest* **67:** 1574-9.

Rezvani I, Collipp PJ, DiGeorge AM (1973). Evaluation of screening tests for urinary mucopolysaccharides. *Pediatrics* **52:** 64-8.

Richardson MP, Strange BA, Dolan RJ (2004). Encoding of emotional memories depends on amygdala and hippocampus and their interactions. *Nat Neurosci* **7:** 278-85.

Rigante D, Caradonna P (2004). Secondary skeletal involvement in Sanfilippo syndrome. *QJM* **97:** 205-9.

Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S (2006). Inhibition of Glycosaminoglycan Synthesis Using Rhodamine B in a Mouse Model of Mucopolysaccharidosis Type IIIA. *Pediatr Res* **60:** 309-14.

Roberts RJ, O'Neill KE, Yen CT (1984). DNA sequences from the adenovirus 2 genome. *J Biol Chem* **259:** 13968-75.

Robertson DA, Freeman C, Morris CP, Hopwood JJ (1992). A cDNA clone for human glucosamine-6-sulphatase reveals differences between arylsulphatases and non-arylsulphatases. *Biochem J* **288 (Pt 2):** 539-44.

Robinson AJ, Crawley AC, Auclair D, Weston PF, Hirte C, Hemsley KM, Hopwood JJ (submitted by LDRU). Behavioural characterisation of the alpha-mannosidosis guinea pig.

Robinson AJ, Meedeniya AC, Hemsley KM, Auclair D, Crawley AC, Hopwood JJ (2005). Survival and engraftment of mouse embryonic stem cell-derived implants in the guinea pig brain. *Neurosci Res* **53:** 161-8.

Robinson AJ, Rathjen J, Rathjen PD, Hemsley KM, Hopwood JJ (2006). Embryonic stem cell-derived glial precursor cells as a vehicle for sulphamidase production in the MPS-IIIA mouse brain. In: *9th International Symposium on Mucopolysaccharide and Related Diseases*: Venice, Italy, pp 189.

Rodgers RJ, Johnson NJ, Cole JC, Dewar CV, Kidd GR, Kimpson PH (1996). Plus-maze retest profile in mice: importance of initial stages of trail 1 and response to post-trail cholinergic receptor blockade. *Pharmacol Biochem Behav* **54:** 41-50.

Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, Finberg RW, Brough DE, Kovesdi I, Wickham TJ (1998). The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. *J Virol* **72:** 7909-15.

Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ (1999). Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. *Science* **286:** 1568-71.

Rohrer J, Kornfeld R (2001). Lysosomal hydrolase mannose 6-phosphate uncovering enzyme resides in the trans-Golgi network. *Mol Biol Cell* **12:** 1623-31.

Romano PS, Carvelli L, Lopez AC, Jofre G, Sartor T, Sosa MA (2005). Developmental differences between cation-independent and cation-dependent mannose-6-phosphate receptors in rat brain at perinatal stages. *Brain Res Dev Brain Res* **158:** 23-30.

Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, et al. (1990). Gene transfer into humans--immunotherapy of

patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. *N Engl J Med* **323:** 570-8.

Rosenzweig M, Connole M, Glickman R, Yue SP, Noren B, DeMaria M, Johnson RP (2001). Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. *Blood* **97:** 1951-9.

Ross CJ, Bastedo L, Maier SA, Sands MS, Chang PL (2000). Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. *Hum Gene Ther* **11:** 2117-27.

Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG (1953). Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. *Proc Soc Exp Biol Med* **84:** 570-3.

Roy S, Gao G, Lu Y, Zhou X, Lock M, Calcedo R, Wilson JM (2004). Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. *Hum Gene Ther* **15:** 519-30.

Ruoslahti E (1988). Structure and biology of proteoglycans. *Annu Rev Cell Biol* **4:** 229-55.

Russell WC (2000). Update on adenovirus and its vectors. *J Gen Virol* **81:** 2573-604.

Sahagian GG, Distler J, Jourdian GW (1981). Characterization of a membrane-associated receptor from bovine liver that binds phosphomannosyl residues of bovine testicular beta-galactosidase. *Proc Natl Acad Sci U S A* **78:** 4289-93.

Sakurai K, Iizuka S, Shen JS, Meng XL, Mori T, Umezawa A, Ohashi T, Eto Y (2004). Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice. *Gene Ther* **11:** 1475-81.

Salmivirta M, Lidholt K, Lindahl U (1996). Heparan sulfate: a piece of information. *FASEB J* **10:** 1270-9.

Sands MS, Davidson BL (2006). Gene therapy for lysosomal storage diseases. *Mol Ther* **13:** 839-49.

Sanfilippo SJ, Podosin R, Langer L, Good RA (1963). Mental retardation associated with acid mucopolysaccharidurie (heparitin sulfate type). *J Pediatr* **63:** 837-838.

Sarantis H, Johnson G, Brown M, Petric M, Tellier R (2004). Comprehensive detection and serotyping of human adenoviruses by PCR and sequencing. *J Clin Microbiol* **42:** 3963-9.

Sardiello M, Annunziata I, Roma G, Ballabio A (2005). Sulfatases and sulfatase modifying factors: an exclusive and promiscuous relationship. *Hum Mol Genet* **14:** 3203-17.

Savas PS (2003). Assessment of the functional and histopathological outcome of direct CNS enzyme replacement therapy in a murine model of Mucopolysaccharidosis Type IIIA [Honours thesis]. University of Melbourne.

Savas PS, Hemsley KM, Hopwood JJ (2004). Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. *Mol Genet Metab* **82:** 273-85.

Schagen FH, Ossevoort M, Toes RE, Hoeben RC (2004). Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. *Crit Rev Oncol Hematol* **50:** 51-70.

Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T, Parker CC, Zirzow GC, Oliver K, Tedeschi G, Brady RO, Barton NW (1997). Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. *Ann Neurol* **42:** 613-21.

Schiffmann R, Kopp JB, Austin HAr, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001). Enzyme replacement therapy in Fabry disease: a randomized controlled trial. *JAMA* **285:** 2743-2749.

Schmidt M, Hacein-Bey-Abina S, Wissler M, Carlier F, Lim A, Prinz C, Glimm H, Andre-Schmutz I, Hue C, Garrigue A, Le Deist F, Lagresle C, Fischer A, Cavazzana-Calvo M, von Kalle C (2005). Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. *Blood* **105:** 2699-706.

Schmitz H, Wigand R, Heinrich W (1983). Worldwide epidemiology of human adenovirus infections. *Am J Epidemiol* **117:** 455-66.

Schowalter DB, Meuse L, Wilson CB, Linsley PS, Kay MA (1997). Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression. *Gene Ther* **4:** 853-60.

Schulze C, Baumgartner W (1998). Nested polymerase chain reaction and in situ hybridization for diagnosis of canine herpesvirus infection in puppies. *Vet Pathol* **35:** 209-17.

Scott HS, Blanch L, Guo X-H, Freeman VC, Orsborn A, Baker E, Sutherland GR, Morris P, Hopwood JJ (1995). Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. *Nat Genet* **11:** 465-467.

Seiradake E, Billet O, Perreau M, Schoehn G, Wodrich H, Lortat-Jacob H, Kremer EJ, Cusack S (in preparation). The sialic acid binding and HA properties of canine adenovirus 2 and Ad37.

Seiradake E, Lortat-Jacob H, Billet O, Kremer EJ, Cusack S (2006). Structural and mutational analysis of human Ad37 and canine adenovirus 2 fibre heads in complex with the D1 domain of CAR. *J Biol Chem* **281:** 33704-16.

Serguera C, Sarkis C, Ridet JL, Colin P, Moullier P, Mallet J (2001). Primary adult human astrocytes as an ex vivo vehicle for beta-glucuronidase delivery in the brain. *Mol Ther* **3:** 875-881.

Sevin C, Aubourg P, Cartier N (2007). Enzyme, cell and gene-based therapies for metachromatic leukodystrophy. *J Inherit Metab Dis* **30:** 175-83.

Sferra TJ, Backstrom K, Wang C, Rennard R, Miller M, Hu Y (2004). Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. *Mol Ther* **10:** 478-91.

Shapiro EG, Lockman LA, Balthazor M, Krivit W (1995). Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. *J Inherit Metab Dis* **18:** 413-429.

Shaw AR, Ziff EB (1980). Transcripts from the adenovirus-2 major late promoter yield a single early family of 3' coterminal mRNAs and five late families. *Cell* **22:** 905-16.

Shen JS, Meng XL, Maeda H, Ohashi T, Eto Y (2004). Widespread gene transduction to the central nervous system by adenovirus in utero: implication for prenatal gene therapy to brain involvement of lysosomal storage disease. *J Gene Med* **6:** 1206-15.

Shen JS, Meng XL, Ohashi T, Eto Y (2002). Adenovirus-mediated prenatal gene transfer to murine central nervous system. *Gene Ther* **9:** 819-23.

Shen JS, Watabe K, Ohashi T, Eto Y (2001a). Intraventricular administration of recombinant adenovirus to neonatal twitcher mouse leads to clinicopathological improvements. *Gene Ther* **8:** 1081-7.

Shen WY, Lai MC, Beilby J, Barnett NL, Liu J, Constable IJ, Rakoczy PE (2001b). Combined effect of cyclosporine and sirolimus on improving the longevity of recombinant adenovirus-mediated transgene expression in the retina. *Arch Ophthalmol* **119:** 1033-43.

Sheppard M, Werner W, Tsatas E, McCoy R, Prowse S, Johnson M (1998). Fowl adenovirus recombinant expressing VP2 of infectious bursal disease virus induces protective immunity against bursal disease. *Arch Virol* **143:** 915-30.

Short JJ, Pereboev AV, Kawakami Y, Vasu C, Holterman MJ, Curiel DT (2004). Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. *Virology* **322:** 349-59.

Shull R, Lu X, Dube I, Lutzko C, Kruth S, Abrams-Ogg A, Kiem HP, Goehle S, Schuening F, Millan C, Carter R (1996). Humoral immune response limits gene therapy in canine MPS I. *Blood* **88:** 377-9.

Shull RM, Hastings NE, Selcer RR, Jones JB, Smith JR, Cullen WC, Constantopoulos G (1987). Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system. *J Clin Invest* **79:** 435-43.

Simonaro CM, Haskins ME, Abkowitz JL, Brooks DA, Hopwood JJ, Zhang J, Schuchman EH (1999). Autologous transplantation of retrovirally transduced bone marrow or neonatal blood cells into cats can lead to long-term engraftment in the absence of myeloablation. *Gene Ther* **6:** 107-113.

Singec I, Jandial R, Crain A, Nikkhah G, Snyder EY (2007). The leading edge of stem cell therapeutics. *Annu Rev Med* **58:** 313-28.

Sivakumur P, Wraith JE (1999). Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. *J Inherit Metab Dis* **22:** 849-50.

Skorupa AF, Fisher KJ, Wilson JM, Parente MK, Wolfe JH (1999). Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. *Exp Neurol* **160:** 17-27.

Sleeper MM, Fornasari B, Ellinwood NM, Weil MA, Melniczek J, O'Malley TM, Sammarco CD, Xu L, Ponder KP, Haskins ME (2004). Gene Therapy Ameliorates Cardiovascular Disease in Dogs With Mucopolysaccharidosis VII. *Circulation* **110:** 815-20.

Smith Y, Raju DV, Pare JF, Sidibe M (2004). The thalamostriatal system: a highly specific network of the basal ganglia circuitry. *Trends Neurosci* **27:** 520-7.

Snyder EY, Taylor RM, Wolfe JH (1995). Neural Progenitor Cell Engraftment Corrects Lysosomal Storage Throughout the MPS VII Mouse Brain. *Nature* **374:** 367-370.

Soper BW, Lessard MD, Jude CD, Schuldt AJ, Bunte RM, Barker JE (2003). Successful allogeneic neonatal bone marrow transplantation devoid of myeloablation requires costimulatory blockade. *J Immunol* **171:** 3270-7.

Sotak BN, Hnasko TS, Robinson S, Kremer EJ, Palmiter RD (2005). Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding. *Brain Res* **1061:** 88-96.

Soudais C, Boutin S, Hong SS, Chillon M, Danos O, Bergelson JM, Boulanger P, Kremer EJ (2000). Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway. *J Virol* **74:** 10639-49.

Soudais C, Boutin S, Kremer EJ (2001a). Characterization of cis-acting sequences involved in canine adenovirus packaging. *Mol Ther* **3:** 631-40.

Soudais C, Laplace-Builhe C, Kissa K, Kremer EJ (2001b). Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. *FASEB J* **15:** 2283-5.

Soudais C, Skander N, Kremer EJ (2004). Long-term in vivo transduction of neurons throughout the rat CNS using novel helper-dependent CAV-2 vectors. *FASEB J* **18:** 391-3.

Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006). High incidence of later-onset fabry disease revealed by newborn screening. *Am J Hum Genet* **79:** 31-40.

Spranger J (1972). The systemic mucopolysaccharidoses. *Ergeb Inn Med Kinderheilkd* **32:** 165-265.

Squire LR (1992). Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. *Psychol Rev* **99:** 195-231.

Stein CS, Ghodsi A, Derksen T, Davidson BL (1999). Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. *J Virol* **73:** 3424-3429.

Stein CS, Pemberton JL, van Rooijen N, Davidson BL (1998). Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus. *Gene Ther* **5:** 431-9.

Stevenson B, Nicolson R (2002). Serology of Australian, New Zealand, Hong Kong and Singapore Rodent Colonies. [Online, accessed 27 Nov, 2006] http://www.imvs.sa.gov.au/vet/research/MVMS_Anzslas2002.pdf

Stevenson PG, Hawke S, Sloan DJ, Bangham CR (1997). The immunogenicity of intracerebral virus infection depends on anatomical site. *J Virol* **71:** 145-51.

Stewart PL, Fuller SD, Burnett RM (1993). Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. *EMBO J* **12:** 2589-99.

Stokes CE, Murphy D, Paton JF, Kasparov S (2003). Dynamics of a transgene expression in acute rat brain slices transfected with adenoviral vectors. *Exp Physiol* **88:** 459-66.

Stone D, Xiong W, Williams JC, David A, Lowenstein PR, Castro MG (2003). Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain

inflammation, but delays immune system-mediated elimination of transgene expression. *Mol Ther* **8:** 400-11.

Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D (1999). Immune response to green fluorescent protein: implications for gene therapy. *Gene Ther* **6:** 1305-12.

Suomalainen M, Nakano MY, Keller S, Boucke K, Stidwill RP, Greber UF (1999). Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. *J Cell Biol* **144:** 657-72.

Sutherland LS, Hemsley KM, Hopwood JJ (submitted by LDRU). Characterisation of Primary Cultured Brain Cells Isolated from Newborn and Adult Mucopolysaccharidosis Type IIIA Mice.

Tada T, Nguyen JB, Hitoshi Y, Watson NP, Dunn JF, Ohara S, Nagano S, Kosai K, Israel MA (2005). Diffuse encephaloventriculitis and substantial leukoencephalopathy after intraventricular administration of recombinant adenovirus. *Neurol Res* **27:** 378-86.

Takakusaki Y, Hisayasu S, Hirai Y, Shimada T (2005). Coexpression of formylglycine-generating enzyme is essential for synthesis and secretion of functional arylsulfatase A in a mouse model of metachromatic leukodystrophy. *Hum Gene Ther* **16:** 929-36.

Takaura N, Yagi T, Maeda M, Nanba E, Oshima A, Suzuki Y, Yamano T, Tanaka A (2003). Attenuation of ganglioside GM1 accumulation in the brain of GM1 gangliosidosis mice by neonatal intravenous gene transfer. *Gene Ther* **10:** 1487-93.

Taylor RM, Farrow BR, Stewart GJ (1992). Amelioration of clinical disease following bone marrow transplantation in fucosidase-deficient dogs. *Am J Med Genet* **42:** 628-32.

Taylor RM, Wolfe JH (1997). Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. *Nat Med* **3:** 771-4.

Teixeira RM, Duarte FS, De Lima TC (2004). Behavioral and immunological effects of substance P in female and male mice. *Pharmacol Biochem Behav* **79:** 1-9.

Tessitore A, Faella A, Parisi F, Haskins M, Auricchio A (2006). AAV-mediated gene transfer to muscle and liver of MPS VI animal models. In: *9th International Symposium on Mucopolysaccharide and Related Diseases*: Venice, Italy, pp 62.

Tettamanti G (2003). Ganglioside/glycosphingolipid turnover: New concepts. *Glycoconj J* **20:** 301-317.

Themis M, Waddington SN, Schmidt M, von Kalle C, Wang Y, Al-Allaf F, Gregory L, Nivsarkar M, Themis M, Holder M, Buckley SMK, Dighe N, Ruthe A, Mistry A, Bigger B, Thrasher AJ, Coutelle C (2006). Oncogenesis Following Delivery of Lentiviral Vectors to Fetal and Neonatal Mice. *Mol Ther* **13:** S320.

Themis M, Waddington SN, Schmidt M, von Kalle C, Wang Y, Al-Allaf F, Gregory LG, Nivsarkar M, Holder MV, Buckley SM, Dighe N, Ruthe AT, Mistry A, Bigger B, Rahim A, Nguyen TH, Trono D, Thrasher AJ, Coutelle C (2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. *Mol Ther* **12:** 763-71.

Thomas CE, Birkett D, Anozie I, Castro MG, Lowenstein PR (2001a). Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. *Mol Ther* **3:** 36-46.

Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR (2000). Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. *Proc Natl Acad Sci U S A* **97:** 7482-7.

Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR (2001b). Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. *Hum Gene Ther* **12:** 839-46.

Thompson JN, Jones MZ, Dawson G, Huffman PS (1992). N-acetylglucosamine 6-sulphatase deficiency in a Nubian goat: a model of Sanfilippo syndrome type D (mucopolysaccharidosis IIID). *J Inherit Metab Dis* **15:** 760-8.

Thornhill AR, Snow K (2002). Molecular diagnostics in preimplantation genetic diagnosis. *J Mol Diagn* **4:** 11-29.

Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS (1996). The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. *J Virol* **70:** 2296-306.

Tomko RP, Xu R, Philipson L (1997). HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. *Proc Natl Acad Sci U S A* **94:** 3352-6.

Trotman LC, Mosberger N, Fornerod M, Stidwill RP, Greber UF (2001). Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. *Nat Cell Biol* **3:** 1092-100.

Tsien RY (1998). The green fluorescent protein. *Annu Rev Biochem* **67:** 509-44.

Uchida T, Kajiwara K, Ideguchi M, Yoshikawa K, Morioka J, Suzuki M (2001). Co-administration of adenovirus vector expressing CTLA4-Ig prolongs transgene expression in the brain of mice sensitized with adenovirus. *Brain Res* **898:** 272-80.

Upchurch M, Wehner JM (1988). Differences between inbred strains of mice in Morris water maze performance. *Behav Genet* **18:** 55-68.

Urayama A, Grubb JH, Sly WS, Banks WA (2004). Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. *Proc Natl Acad Sci U S A* **101:** 12658-63.

Van Dam D, Lenders G, De Deyn PP (2006). Effect of Morris water maze diameter on visual-spatial learning in different mouse strains. *Neurobiol Learn Mem* **85:** 164-72.

van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA (1981). Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). *Clin Genet* **20:** 152-60.

Van Hove JL, Wevers RA, Van Cleemput J, Moerman P, Sciot R, Matthijs G, Schollen E, de Jong JG, Carey WF, Muller V, Nicholls C, Perkins K, Hopwood JJ (2003). Late-Onset visceral presentation with cardiomyopathy and without neurological symptoms of adult Sanfilippo A syndrome. *Am J Med Genet A* **118:** 382-7.

van Raaij MJ, Mitraki A, Lavigne G, Cusack S (1999). A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein. *Nature* **401:** 935-8.

Vellinga J, Van der Heijdt S, Hoeben RC (2005). The adenovirus capsid: major progress in minor proteins. *J Gen Virol* **86:** 1581-8.

Vellodi A, Young E, New M, Pot-Mees C, Hugh-Jones K (1992). Bone marrow transplantation for Sanfilippo disease type B. *J Inherit Metab Dis* **15:** 911-8.

Vervoort R, Gitzelmann R, Bosshard N, Maire I, Liebaers I, Lissens W (1998). Low beta-glucuronidase enzyme activity and mutations in the human beta-glucuronidase gene in mild mucopolysaccharidosis type VII, pseudodeficiency and a heterozygote. *Hum Genet* **102:** 69-78.

Vilquin JT, Guerette B, Kinoshita I, Roy B, Goulet M, Gravel C, Roy R, Tremblay JP (1995). FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. *Hum Gene Ther* **6:** 1391-401.

Virta S, Rapola J, Jalanko A, Laine M (2006). Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse. *J Gene Med* **8:** 699-706.

Vives RR, Lortat-Jacob H, Chroboczek J, Fender P (2004). Heparan sulfate proteoglycan mediates the selective attachment and internalization of serotype 3 human adenovirus dodecahedron. *Virology* **321:** 332-40.

Vogler C, Levy B, Galvin NJ, Thorpe C, Sands MS, Barker JE, Baty J, Birkenmeier EH, Sly WS (1999). Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. *Pediatr Res* **45:** 838-44.

Vogler C, Levy B, Grubb JH, Galvin N, Tan Y, Kakkis E, Pavloff N, Sly WS (2005). Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. *Proc Natl Acad Sci U S A* **102:** 14777-82.

Voikar V, Koks S, Vasar E, Rauvala H (2001). Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. *Physiol Behav* **72:** 271-81.

Voikar V, Polus A, Vasar E, Rauvala H (2005). Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences. *Genes Brain Behav* **4:** 240-52.

Voikar V, Vasar E, Rauvala H (2004). Behavioral alterations induced by repeated testing in C57BL/6J and 129S2/Sv mice: implications for phenotyping screens. *Genes Brain Behav* **3:** 27-38.

Volpers C, Kochanek S (2004). Adenoviral vectors for gene transfer and therapy. *J Gene Med* **6 Suppl 1:** S164-71.

Wada R, Tifft CJ, Proia RL (2000). Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. *Proc Natl Acad Sci U S A* **97:** 10954-9.

Waddington SN, Kennea NL, Buckley SM, Gregory LG, Themis M, Coutelle C (2004). Fetal and neonatal gene therapy: benefits and pitfalls. *Gene Ther* **11 Suppl 1:** S92-7.

Wahlsten D, Cooper SF, Crabbe JC (2005). Different rankings of inbred mouse strains on the Morris maze and a refined 4-arm water escape task. *Behav Brain Res* **165:** 36-51.

Walkley S (2005). Therapeutic compositions and methods of treating glycolipid storage related disorders. [Online, accessed 2007, 24 February] http://www.freepatentsonline.com/20050032841.html

Walkley SU (1998). Cellular Pathology of Lysosomal Storage Disorders. *Brain Pathol* **8:** 175-193.

Walkley SU (2004). Secondary accumulation of gangliosides in lysosomal storage disorders. *Semin Cell Dev Biol* **15:** 433-44.

Walkley SU, Thrall MA, Dobrenis K, Huang M, March PA, Siegel DA, Wurzelmann S (1994). Bone Marrow Transplantation Corrects the Enzyme Defect in Neurons of the Central Nervous System in a Lysosomal Storage Disease. *Proc Natl Acad Sci U S A* **91:** 2970-2974.

Wang B, O'Malley TM, Xu L, Vite C, Wang P, O'Donnell PA, Ellinwood NM, Haskins ME, Ponder KP (2006). Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. *Mol Genet Metab* **87:** 8-21.

Watson G, Bastacky J, Belichenko P, Buddhikot M, Jungles S, Vellard M, Mobley WC, Kakkis E (2006). Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. *Gene Ther* **13:** 917-25.

Watson GL, Sayles JN, Chen C, Elliger SS, Elliger CA, Raju NR, Kurtzman GJ, Podsakoff GM (1998). Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. *Gene Ther* **5:** 1642-1649.

Weber B, Blanch L, Clements PR, Scott HS, Hopwood JJ (1996). Cloning and Expression of the Gene Involved in Sanfilippo B Syndrome (Mucopolysaccharidosis III B). *Hum Mol Genet* **5:** 771-777.

Weber B, Guo XH, Wraith JE, Cooper A, Kleijer WJ, Bunge S, Hopwood JJ (1997). Novel Mutations in Sanfilippo-A-Syndrome - Implications for Enzyme Function. *Hum Mol Genet* **6:** 1573-1579.

Wegrzyn G, Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, Liberek A, Wegrzyn A (2006). Gene expression-targeted isoflavone therapy for Sanfilippo disease: in vitro studies on fibroblasts and a pilot clinical trial. In: *9th International Symposium on Mucopolysaccharide and Related Diseases*: Venice, Italy, pp 47.

Wells DJ (2004). Gene therapy progress and prospects: electroporation and other physical methods. *Gene Ther* **11:** 1363-9.

Whitelock JM, Iozzo RV (2005). Heparan sulfate: a complex polymer charged with biological activity. *Chem Rev* **105:** 2745-64.

Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. *Cell* **73:** 309-19.

Wiethoff CM, Wodrich H, Gerace L, Nemerow GR (2005). Adenovirus protein VI mediates membrane disruption following capsid disassembly. *J Virol* **79:** 1992-2000.

Willingham MC, Pastan IH, Sahagian GG, Jourdian GW, Neufeld EF (1981). Morphologic study of the internalization of a lysosomal enzyme by the mannose 6-phosphate receptor in cultured Chinese hamster ovary cells. *Proc Natl Acad Sci U S A* **78:** 6967-71.

Wisnivesky JP, Leopold PL, Crystal RG (1999). Specific binding of the adenovirus capsid to the nuclear envelope. *Hum Gene Ther* **10:** 2187-95.

Wolfe JH, Sands MS, Barker JE, Gwynn B, Rowe LB, Vogler CA, Birkenmeier EH (1992). Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. *Nature* **360:** 749-53.

Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF (2004). Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). *J Pediatr* **144:** 581-8.

Wu Z, Asokan A, Samulski RJ (2006). Adeno-associated virus serotypes: vector toolkit for human gene therapy. *Mol Ther* **14:** 316-27.

Xu F, Ding E, Liao SX, Migone F, Dai J, Schneider A, Serra D, Chen YT, Amalfitano A (2004). Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. *Gene Ther* **11:** 1590-8.

Xu L, Mango RL, Sands MS, Haskins ME, Ellinwood NM, Ponder KP (2002). Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. *Mol Ther* **6:** 745-58.

Yamaguchi A, Katsuyama K, Suzuki K, Kosaka K, Aoki I, Yamanaka S (2003). Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease. *J Mol Med* **81:** 185-93.

Yamaguchi Y (2001). Heparan sulfate proteoglycans in the nervous system: their diverse roles in neurogenesis, axon guidance, and synaptogenesis. *Semin Cell Dev Biol* **12:** 99-106.

Yanagishita M (1985). Inhibition of intracellular degradation of proteoglycans by leupeptin in rat ovarian granulosa cells. *J Biol Chem* **260:** 11075-82.

Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. *Proc Natl Acad Sci U S A* **91:** 4407-11.

Ye X, Robinson MB, Pabin C, Batshaw ML, Wilson JM (2000). Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. *Gene Ther* **7:** 1761-7.

Yogalingam G, Crawley A, Hopwood JJ, Anson DS (1999). Evaluation of fibroblast-mediated gene therapy in a feline model of mucopolysaccharidosis type VI. *Biochim Biophys Acta* **1453:** 284-296.

Yogalingam G, Hopwood JJ (2001). Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. *Hum Mutat* **18:** 264-281.

Yogalingam G, Pollard T, Gliddon B, Jolly RD, Hopwood JJ (2002). Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs. *Genomics* **79:** 150-3.

Zaharia MD, Kulczycki J, Shanks N, Meaney MJ, Anisman H (1996). The effects of early postnatal stimulation on Morris water-maze acquisition in adult mice: genetic and maternal factors. *Psychopharmacology (Berl)* **128:** 227-39.

Zakhartchouk A, Zhou Y, Tikoo SK (2003). A recombinant E1-deleted porcine adenovirus-3 as an expression vector. *Virology* **313:** 377-86.

Zhang HG, Hsu HC, Yang PA, Yang X, Wu Q, Liu Z, Yi N, Mountz JD (2004). Identification of multiple genetic loci that regulate adenovirus gene therapy. *Gene Ther* **11:** 4-14.

Zhao HG, Li HH, Bach G, Schmidtchen A, Neufeld EF (1996). The Molecular Basis of Sanfilippo Syndrome Type B. *Proc Natl Acad Sci U S A* **93:** 6101-6105.

Zheng Y, Rozengurt N, Ryazantsev S, Kohn DB, Satake N, Neufeld EF (2003). Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. *Mol Genet Metab* **79:** 233-44.

Zheng Y, Ryazantsev S, Ohmi K, Zhao HZ, Rozengurt N, Kohn DB, Neufeld EF (2004). Retrovirally transduced bone marrow has a therapeutic effect on brain in the mouse model of mucopolysaccharidosis IIIB. *Mol Genet Metab* **82:** 286-95.

Zhu J, Musco ML, Grace MJ (1999). Three-color flow cytometry analysis of tricistronic expression of eBFP, eGFP, and eYFP using EMCV-IRES linkages. *Cytometry* **37:** 51-9.

Zhu SW, Yee BK, Nyffeler M, Winblad B, Feldon J, Mohammed AH (2006). Influence of differential housing on emotional behaviour and neurotrophin levels in mice. *Behav Brain Res* **169:** 10-20.

Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette PC, Romanczuk H, Ioannou YA, Zeidner KM, Desnick RJ, Cheng SH (1999). Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. *Hum Gene Ther* **10:** 1667-1682.

Ziller C, Stoeckel F, Boon L, Haegel-Kronenberger H (2002). Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector. *Gene Ther* **9:** 537-46.

Zirger JM, Barcia C, Liu C, Puntel M, Mitchell N, Campbell I, Castro M, Lowenstein PR (2006a). Rapid Upregulation of Interferon-Regulated and Chemokine mRNAs upon Injection of 108 International Units, but Not Lower Doses, of Adenoviral Vectors into the Brain. *J Virol* **80:** 5655-9.

Zirger JM, Liu C, Barcia C, Castro MG, Lowenstein PR (2006b). Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors. *Viral Immunol* **19:** 508-17.

Zolotukhin S (2005). Production of recombinant adeno-associated virus vectors. *Hum Gene Ther* **16:** 551-7.

Zou L, Zhou H, Pastore L, Yang K (2000). Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. *Mol Ther* **2:** 105-13.

Addenda

Page 14, line 30: change to “benzodiazepines, chloral hydrate …. trimeprazine tartrate have had some success”.

Page 15, line 4: delete “antipsychotic”.

Page 60, line 15: delete “complete” and replace with “completely”.

Page 69, line 1: change “25 mL” to “25 μL”.

Page 136, line 11: replace with “… was able to have…”

Page 137, lines 1-4: change to “Injection of 10^8 or 10^9 particles/μL CAV-NS at birth did not significantly impact on the concentration of HNS-UA detected in the olfactory bulb at both 1-wk and 6-wks post-injection, given the variation in the PBS-treated MPS IIIA group at these time-points (p=0.80, p=0.30).

Page 145, line 30: delete final sentence and replace with “The operator was placed at a point equidistant from an open and closed arm”.

Page 153, line 17: change “marginally significant” to “approached significance”.

Page 160, paragraph 2: after “1- 7-days after the initial exposure” insert the sentence “This discrepancy may relate to the time difference between the first trial and subsequent re-exposure to the EPM apparatus in these studies (less than 1 week) compared to the 3 weeks interval utilised in our study”.

Page 162, line 5: delete “Neither antibodies towards rhNS nor”.

Page 179, line 5: insert after the end of sentence “CAV-NS treatment did not increase the amount of NS activity measured in unaffected or MPS IIIA mice”.

Page 203, line 18: change “Compared to PBS-treated animals, CAV-NS treatment had no effect on the functional changes associated with MPS IIIA.” to read: “No functional changes were able to be demonstrated between PBS- and CAV-NS-treated MPS IIIA animals.”